Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.1.1.8 - cholinesterase and Organism(s) Homo sapiens

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Spontaneous
Butyrylcholinesterase activity and lymphocyte subpopulations in peripheral blood of Kuwaiti women experiencing recurrent spontaneous abortion.
Ratio of immunochemically determined amniotic fluid acetylcholinesterase to butyrylcholinesterase in the differential diagnosis of fetal abnormalities.
[BEHAVIOR OF THE CHOLINESTERASE ACTIVITY IN THE BLOOD AND IN PLACENTAL TISSUE DURING THE 1ST MONTHS OF PHYSIOLOGICAL PREGNANCY AND IN SPONTANEOUS ABORTIONS.]
Abortion, Threatened
[Changes in the concentration of copper and ceruloplasmin, and cholinesterase activity in the blood in threatened abortion]
acetylcholinesterase deficiency
Congenital myasthenic syndromes.
[Congenital myasthenic syndromes: phenotypic expression and pathophysiological characterisation]
Acidosis
Chronotropic and dromotropic actions of acetylcholine on the developing fetal heart.
Organophosphate poisoning: modifications in acid base equilibrium and use of sodium bicarbonate as an aid in the treatment of toxicity in dogs.
Suspected chlorpyrifos toxicosis in a llama, and plasma pseudocholinesterase activity in llamas given chlorpyrifos.
[Severe medical sequelae in heroin addicts]
Acidosis, Lactic
Acute toxicity of methyl isocyanate in mammals. II. Induction of hyperglycemia, lactic acidosis, uraemia, and hypothermia in rats.
Acne Vulgaris
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2?years of age - a multicenter retrospective study.
Acquired Immunodeficiency Syndrome
Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients.
Concentrations of magnesium, zinc and copper in serum of patients with acquired immuno-deficiency syndrome.
[Research on risk factors of short-term outcome in AIDS patients with pneumocystis pneumonia].
Acromegaly
The evaluation of hypothalamic somatostatin tone using pyridostigmine and thyrotropin releasing hormone in patients with acromegaly.
Acute Coronary Syndrome
Butyrylcholinesterase Activity Predicts Long-Term Survival in Patients with Coronary Artery Disease.
Butyrylcholinesterase predicts cardiac mortality in young patients with acute coronary syndrome.
Low Serum-Butyrylcholinesterase Activity as a Prognostic Marker of Mortality Associates with Poor Cardiac Function in Acute Myocardial Infarction.
Acute Kidney Injury
Activation of ?7 Nicotinic Acetylcholine Receptor Ameliorates Zymosan-Induced Acute Kidney Injury in BALB/c Mice.
Clinical characteristics and outcomes of critically ill COVID-19 patients in Sfax, Tunisia.
Predictors of Morbidity and Mortality in Organophosphorus Poisoning: A Case Study in Rural Hospital in Karnataka, India.
Adenocarcinoma
HER-2 amplification but not butyrylcholinesterase multability reflects aggressiveness of European-originated ovarian tumors.
Production of butyrylcholinesterase by Caco-2 cells: lack of relationship with triglyceride production.
Serum pseudocholinesterase levels in murine C3H mammary adenocarcinoma.
Adrenocortical Hyperfunction
Serum paraoxonase 1 and butyrylcholinesterase in dogs with hyperadrenocorticism.
Aggressive Periodontitis
Determination of pseudocholinesterase activity in the gingival crevicular fluid, saliva, and serum from patients with juvenile periodontitis and rapidly progressive periodontitis.
Airway Obstruction
Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing.
[Emergency from anesthesia in small children. From laryngospasm to prolonged apnea]
alcohol dehydrogenase deficiency
Ecogenetic and pharmacogenetic studies in Hungary.
Ecogenetic studies in Atacameño Indians.
Alcohol Withdrawal Delirium
[Proceedings: Relationship of serum cholinesterase level in chronic alcoholic liver disease and appearance of delirium tremens: therapeutic effect of oximes]
Alopecia
[Clinical and biochemical alterations in rats treated with high doses of vitamin A]
Alzheimer Disease
"Clicking" fragment leads to novel dual-binding cholinesterase inhibitors.
"Value for money" in treating Alzheimer's disease with the new cholinesterase inhibitors.
(±)-BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3? Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease.
1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer's disease.
1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases.
11: disorders of memory and intellect.
2-Hydroxy-N-phenylbenzamides and Their Esters Inhibit Acetylcholinesterase and Butyrylcholinesterase.
6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment.
9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model.
A 10-year perspective on donepezil.
A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors.
A case with cholinesterase inhibitor responsive asymmetric posterior cortical atrophy.
A clinical overview of cholinesterase inhibitors in Alzheimer's disease.
A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease.
A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
A gorge-spanning, high-affinity cholinesterase inhibitor to explore beta-amyloid plaques.
A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.
A modified binary particle swarm optimization with a machine learning algorithm and molecular docking for QSAR modelling of cholinesterase inhibitors.
A molecular modeling study of components of the ginger (Zingiber officinale) extract inside human butyrylcholinesterase: implications for Alzheimer disease.
A Multi-layered Variable Selection Strategy for QSAR Modeling of Butyrylcholinesterase Inhibitors.
A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase.
A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
A new way of data interpretation for cognition tests in rats used to characterise six choline esterase inhibitors with heterocyclic nitrogen bridgehead structure. Application in Alzheimer therapy.
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
A palliative care perspective on deprescribing cholinesterase inhibitors in Alzheimer's disease.
A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.
A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer's disease.
A phase II trial of huperzine A in mild to moderate Alzheimer disease.
A Platform for Screening Potential Anticholinesterase Fractions and Components Obtained from Anemarrhena asphodeloides Bge for Treating Alzheimer's Disease.
A population-based study of dosing and persistence with anti-dementia medications.
A potent and selective tacrine analog--biomembrane permeation and physicochemical characterization.
A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.
A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease.
A Randomized Phase I Study of Methanesulfonyl Fluoride, an Irreversible Cholinesterase Inhibitor, for the Treatment of Alzheimer's Disease.
A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease.
A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer's Disease Patients.
A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes.
A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.
A review on cholinesterase inhibitors for Alzheimer's disease.
A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease.
A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease.
A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease.
A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.
A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
A systematic review of carbohydrate-based bioactive molecules for Alzheimer's disease.
A systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer's disease.
A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE.
A three-country randomized controlled trial of a psychosocial intervention for caregivers combined with pharmacological treatment for patients with Alzheimer disease: effects on caregiver depression.
A top 5 list for French general practice.
Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.
Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease.
Acetylcholinesterase activities and monoamine metabolite levels in the cerebrospinal fluid of patients with Alzheimer's disease.
Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type.
Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation.
Acetylcholinesterase and butyrylcholinesterase glycoforms are biomarkers of Alzheimer's disease.
Acetylcholinesterase and butyrylcholinesterase inhibition by nectriapyrone and tryptophol isolated from endophytic fungus Phomopsis sp.
Acetylcholinesterase and butyrylcholinesterase inhibitory activities of khellactone coumarin derivatives isolated from Peucedanum japonicum Thurnberg.
Acetylcholinesterase and butyrylcholinesterase inhibitory activity of Pinus species essential oils and their constituents.
Acetylcholinesterase and its association with heparan sulphate proteoglycans in cortical amyloid deposits of Alzheimer's disease.
Acetylcholinesterase Inhibition of Diversely Functionalized Quinolinones for Alzheimer's Disease Therapy.
Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
Acetylcholinesterase inhibitors: SAR and kinetic studies on omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyaryl derivatives.
Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts.
Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine.
Acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibition studies and antioxidant activities of 33 Scutellaria L. taxa from Turkey.
aChE and BuChE inhibition by rivastigmin have no effect on peripheral insulin resistance in elderly patients with Alzheimer disease.
Acquired Localized Hypertrichosis Induced by Rivastigmine.
Acridine-induced subcellular and functional changes in isolated human hepatocytes in vitro.
Acteylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines.
Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease.
Active compounds from a diverse library of triazolothiadiazole and triazolothiadiazine scaffolds: synthesis, crystal structure determination, cytotoxicity, cholinesterase inhibitory activity, and binding mode analysis.
Activities and kinetic properties of lumbar cerebrospinal fluid cholinesterases in relation to clinical diagnosis, severity, and progression of Alzheimer's disease.
Acute Effects of Muscarinic M1 Receptor Modulation on A?PP Metabolism and Amyloid-? Levels in vivo: A Microdialysis Study.
Acute nicotine effects on auditory sensory memory in tacrine-treated and nontreated patients with Alzheimer's disease: an event-related potential study.
Adherence to cholinesterase inhibitors in Alzheimer's disease: a review.
Adherence to cholinesterase inhibitors in patients with Alzheimer's disease.
Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease.
Advances in Alzheimer's disease. A review for the family physician.
Advances in the treatment of Alzheimer's disease.
Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Advances in the treatment of cognitive impairment in Parkinson's disease.
Adverse drug events affecting medication persistence with rivastigmine patch application.
Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains.
Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome.
Ajmalicine and its Analogues against AChE and BuChE for the Management of Alzheimer's Disease: An In-silico study.
Alanine-to-threonine substitutions and amyloid diseases: Butyrylcholinesterase as a case study.
Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.
Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.
Altered glycosylation of cerebrospinal fluid butyrylcholinesterase in Alzheimer's disease.
Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice.
Alzheimer Disease: Pharmacologic and Nonpharmacologic Therapies for Cognitive and Functional Symptoms.
Alzheimer's dementia: current data review.
Alzheimer's disease and the glutamate NMDA receptor.
Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection?
Alzheimer's disease in France: too many patients exposed to drug interactions involving cholinesterase inhibitors.
Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement.
Alzheimer's Disease.
Alzheimer's disease.
Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Alzheimer's disease: early diagnosis and treatment.
Alzheimer's disease: recent advances in etiology, diagnosis, and management.
Alzheimer's disease: the pharmacological pathway.
Amaryllidaceae Alkaloids of Norbelladine-Type as Inspiration for Development of Highly Selective Butyrylcholinesterase Inhibitors: Synthesis, Biological Activity Evaluation, and Docking Studies.
Amelioration of scopolamine-induced amnesia by phosphatidylserine and curcumin in the day-old chick.
Aminoalcoholate-driven tetracopper(II) cores as dual acetyl and butyrylcholinesterase inhibitors: Experimental and theoretical elucidation of mechanism of action.
Amiridine-piperazine hybrids as cholinesterase inhibitors and potential multitarget agents for Alzheimer's disease treatment.
Amyloid precursor protein 96-110 and beta-amyloid 1-42 elicit developmental anomalies in sea urchin embryos and larvae that are alleviated by neurotransmitter analogs for acetylcholine, serotonin and cannabinoids.
Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.
Amyloid-? peptides act as allosteric modulators of cholinergic signalling through formation of soluble BA?ACs.
An audit of a specialist old age psychiatry liaison service to a medium and a high secure forensic psychiatry unit.
An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
An Efficient Synthesis of bi-Aryl Pyrimidine Heterocycles: Potential New Drug Candidates to Treat Alzheimer's Disease.
An evaluation of neonicotinoids' potential to inhibit human cholinesterases: Protein-ligand docking and interaction profiling studies.
An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
An Overview on Natural Cholinesterase Inhibitors - A Multi-Targeted Drug Class - and Their Mass Production.
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease.
Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K).
Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease.
Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease.
Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles.
Antagonism of anticholinesterase (DFP) toxicity by donepezil plus scopolamine: a preliminary study.
Anti-Alzheimer potential, metabolomic profiling and molecular docking of green synthesized silver nanoparticles of Lampranthus coccineus and Malephora lutea aqueous extracts.
Anti-Alzheimer's disease activity of compounds from the root bark of Morus alba L.
Anti-Alzheimer's multitarget-directed ligands with serotonin 5-HT6 antagonist, butyrylcholinesterase inhibitory, and antioxidant activity.
Antibacterial, antioxidant, anti-cholinesterase potential and flavonol glycosides of Biscutella raphanifolia (Brassicaceae).
Anticholinesterase activity of plastoquinones from Sargassum sagamianum: lead compounds for Alzheimer's disease therapy.
Anticholinesterase-induced symptoms improved by pacemaker implantation in patients with Alzheimer's disease: analysis of 6 cases.
Antioxidant activity and acetylcholinesterase inhibition of grape skin anthocyanin (GSA).
Antioxidant and Cholinesterase Inhibitory Activity of a New Peptide From Ziziphus jujuba Fruits.
Antioxidant properties of eugenol, butylated hydroxylanisole, and butylated hydroxyl toluene with key biomolecules relevant to Alzheimer's diseases-In vitro.
Antioxidant, Antidiabetic, and Anticholinesterase Activities and Phytochemical Profile of Azorella glabra Wedd.
Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.
ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study.
Apolipoprotein ?4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.
Aporphines and Alzheimer's disease: Towards a Medical Approach Facing the Future.
Aporphinoid Alkaloids Derivatives as Selective Cholinesterases Inhibitors: Biological Evaluation and Docking Study.
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Arylbenzofurans from the Root Bark of Morus alba as Triple Inhibitors of Cholinesterase, ?-Site Amyloid Precursor Protein Cleaving Enzyme 1, and Glycogen Synthase Kinase-3?: Relevance to Alzheimer's Disease.
Assessment and treatment of dementia in medical patients.
Assessment of cholinesterase and tyrosinase inhibitory and antioxidant effects of Hypericum perforatum L. (St. John's wort)
Assessment of enzyme inhibitory and antioxidant activities of lignans from Taxus baccata L.
Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease.
Association analysis between K and -116A variants of butyrylcholinesterase and Alzheimer's disease in a Brazilian population.
Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
Association between low-density lipoprotein receptor-related protein gene, butyrylcholinesterase gene and Alzheimer' s disease in Chinese.
Association of a salivary acetylcholinesterase with Alzheimer's disease and response to cholinesterase inhibitors.
Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease.
Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.
Attenuation of functional hyperemia to visual stimulation in mild Alzheimer's disease and its sensitivity to cholinesterase inhibition.
Australian population trends and disparities in cholinesterase inhibitor use, 2003 to 2010.
Axo-axonal interaction in autonomic regulation of the cerebral circulation.
Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors.
BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia.
Benefit-risk considerations in the treatment of dementia with Lewy bodies.
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease.
Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
Benzoic acid-derived nitrones: A new class of potential acetylcholinesterase inhibitors and neuroprotective agents.
Benzylpiperidine-Linked Diarylthiazoles as Potential Anti-Alzheimer's Agents: Synthesis and Biological Evaluation.
Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer's Disease.
Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.
Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs.
Biochemical and Histochemical Comparison of Cholinesterases in Normal and Alzheimer Brain Tissues.
Biochemical Differentiation of Cholinesterases from Normal and Alzheimer's Disease Cortex.
Biological Activities of Aerial Parts Extracts of Euphorbia characias.
Biological Evaluation of Endophytic Fungus, Chaetomium globosum JN711454, as Potential Candidate for Improving Drug Discovery.
Biophenols: Enzymes (?-secretase, Cholinesterases, histone deacetylase and tyrosinase) inhibitors from olive (Olea europaea L.).
Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia.
Blood markers in Alzheimer disease: subnormal acetylcholinesterase and butyrylcholinesterase in lymphocytes and erythrocytes.
Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.
BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.
Butyrycholinesterase K variant and Alzheimer's disease.
Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem.
Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease.
Butyrylcholinesterase attenuates amyloid fibril formation in vitro.
Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype.
Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-? peptide in mice.
Butyrylcholinesterase is associated with ?-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease.
Butyrylcholinesterase K and Apolipoprotein ?4 Affect Cortical Thickness and Neuropsychiatric Symptoms in Alzheimer's Disease.
Butyrylcholinesterase K and Apolipoprotein E-?4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis.
Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients.
Butyrylcholinesterase K variant and cerebral amyloid angiopathy.
Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland.
Butyrylcholinesterase radioligands to image Alzheimer's disease brain.
Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain).
Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease.
Butyrylcholinesterase-knockout reduces brain deposition of fibrillar ?-amyloid in an Alzheimer mouse model.
Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment.
Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population.
Can Persistence With Cholinesterase Inhibitor Treatment Lower Mortality and Health-Care Costs Among Patients With Alzheimer's Disease? A Population-Based Study in Taiwan.
Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study.
Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
Capillary zone electrophoresis determination of galanthamine in biological fluids and pharmaceutical preparatives: experimental design and artificial neural network optimization.
Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease.
Carbazole-based semicarbazones and hydrazones as multifunctional anti-Alzheimer agents.
Cardiac safety of donepezil in elderly patients with Alzheimer disease.
Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.
Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.
Caregiver acceptance of adverse effects and use of cholinesterase inhibitors in Alzheimer's disease.
Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis.
Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial.
Causes of syncope in patients with Alzheimer's disease treated with donepezil.
CDR State Transition Probabilities in Alzheimer's Disease with and without Cholinesterase Inhibitor Intervention in an Observational Cohort.
Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease.
Cerebral white matter changes and rate of progression of dementia during cholinesterase inhibitor treatment: a retrospective cohort study.
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
Cerebrolysin: a review of its use in dementia.
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Cerebrovascular Pathology and Responsiveness to Treatment in Alzheimer's Disease: A Systematic Review.
Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment.
Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development--a study of molecular forms.
Changes in brain cholinesterases in senile dementia of Alzheimer type.
Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: A microdialysis study.
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease : a nonrandomised controlled trial with magnetic resonance spectroscopy.
Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors.
Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice.
Chemical Characterization of Narcissus poeticus from Sirente -Velino (Apennines - Italy): Galantamine Accumulation and Distribution of Allergenic Compounds in the Flower.
Chemical composition of the essential oil and hexane extract of Salvia chionantha and their antioxidant and anticholinesterase activities.
Chemical composition, antioxidant and anticholinesterase activity of the essential oil of algerian cachrys sicula L.
Chemical composition, biological properties and bioinformatics analysis of two Caesalpina species: A new light in the road from nature to pharmacy shelf.
Chemistry and functional properties in prevention of neurodegenerative disorders of five Cistus species essential oils.
Chinese Medicine for Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Trials.
Chlorinated tacrine analogs: Design, synthesis and biological evaluation of their anti-cholinesterase activity as potential treatment for Alzheimer's disease.
Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management.
Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
Cholinergic enhancement of frontal lobe activity in mild cognitive impairment.
Cholinergic foundations of Alzheimer's disease therapy.
Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?
Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis.
Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type.
Cholinesterase Activity and mRNA Level of Nicotinic Acetylcholine Receptors (alpha4 and beta2 Subunits) in Blood of Elderly Chinese Diagnosed as Alzheimer's Disease.
Cholinesterase activity and mRNA level of nicotinic acetylcholine receptors (alpha4 and beta2 Subunits) in blood of elderly Chinese diagnosed as Alzheimer's disease.
Cholinesterase activity in the plaques, tangles and angiopathy of Alzheimer's disease does not emanate from amyloid.
Cholinesterase and Prolyl Oligopeptidase Inhibitory Activities of Alkaloids from Argemone platyceras (Papaveraceae).
Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
Cholinesterase based amperometric biosensors for assay of anticholinergic compounds.
Cholinesterase enzymes in the blood of patients with Alzheimer's disease.
Cholinesterase inhibition by derivatives of 2-amino-4,6-dimethylpyridine.
Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
Cholinesterase Inhibition in Alzheimer's Disease: Is Specificity the Answer?
Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health.
Cholinesterase inhibition: is there evidence for disease-modifying effects?
Cholinesterase inhibitor affects the amyloid precursor protein isoforms in patients with Alzheimer's disease.
Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors.
Cholinesterase inhibitor blockade and its prevention by statins of sympathetic alpha7-nAChR-mediated cerebral nitrergic neurogenic vasodilation.
Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
Cholinesterase Inhibitor Donepezil Increases Mitochondrial Biogenesis through AMP-Activated Protein Kinase in the Hippocampus.
Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease.
Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors.
Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease.
Cholinesterase inhibitor therapy for Alzheimer dementia: what do animal models tell us?
Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.
Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease.
Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.
Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease.
Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies.
Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM-Elderly Project.
Cholinesterase inhibitor use is associated with increased plasma levels of anti-Abeta 1-42 antibodies in Alzheimer's disease patients.
Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation.
Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer's disease: a systematic review of randomized controlled trials.
Cholinesterase inhibitors and Alzheimer's disease outcomes.
Cholinesterase Inhibitors and Behavioral & Psychological Symptoms of Alzheimer's Disease.
Cholinesterase inhibitors and beyond.
Cholinesterase inhibitors and Gingko extracts--are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration.
Cholinesterase inhibitors and memantine have a role in the treatment of Alzheimer's disease.
Cholinesterase inhibitors and memory.
Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs as Alzheimer's disease therapies: an updated umbrella review of systematic reviews and meta-analyses.
Cholinesterase inhibitors and opiate antagonists in patients with Alzheimer's disease.
Cholinesterase inhibitors are compatible with psychosocial intervention for Alzheimer disease patients suggested by neuroimaging findings.
Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.
Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death.
Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients.
Cholinesterase inhibitors for Alzheimer disease.
Cholinesterase Inhibitors for Alzheimer Disease: Do They Provide More Than Symptomatic Benefits?
Cholinesterase inhibitors for Alzheimer's disease.
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
Cholinesterase inhibitors for Alzheimer's disease: variations in clinical practice in the north-west of England.
Cholinesterase inhibitors for behavioral disturbance in dementia.
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Cholinesterase inhibitors for rarer dementias associated with neurological conditions.
Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly.
Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Cholinesterase inhibitors from the roots of Harpagophytum procumbens.
Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.
Cholinesterase Inhibitors in Alzheimer's Disease.
Cholinesterase Inhibitors in Alzheimer's Disease. Proceedings of a symposium. Sweden, June 1, 1993.
Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
Cholinesterase inhibitors in Alzheimer's disease: efficacy in a non-selected population.
Cholinesterase inhibitors in late-stage Alzheimer's disease.
Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials.
Cholinesterase inhibitors in patients with diabetes mellitus and dementia: an open-cohort study of ~23 000 patients from the Swedish Dementia Registry.
Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.
Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias.
Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients.
Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.
Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia.
Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Cholinesterase inhibitors reduce aggression, wandering, and paranoia in Alzheimer disease.
Cholinesterase inhibitors slow decline in executive functions, rather than memory, in Alzheimer's disease: a 1-year observational study in the sunnybrook dementia cohort.
Cholinesterase inhibitors stabilize Alzheimer disease.
Cholinesterase inhibitors stabilize Alzheimer's disease.
Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease.
Cholinesterase inhibitors: a patent review (2007 - 2011).
Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease.
Cholinesterase Inhibitors: Cardioprotection in Alzheimer's Disease.
Cholinesterase inhibitors: new roles and therapeutic alternatives.
Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Cholinesterase Inhibitory Activities of Selected Halogenated Thiophene Chalcones.
Cholinesterase Inhibitory Activity of Some semi-Rigid Spiro Heterocycles: POM analyses and Crystalline Structure of Pharmacophore Site.
Cholinesterase inhibitory activity of tinosporide and 8-hydroxytinosporide isolated from Tinospora cordifolia: In vitro and in silico studies targeting management of Alzheimer's disease.
Cholinesterase inhibitory effects of Rhizophora lamarckii, Avicennia officinalis, Sesuvium portulacastrum and Suaeda monica: Mangroves inhabiting an Indian coastal area (Vellar Estuary).
Cholinesterase Inhibitory Potential of Quercetin towards Alzheimer's Disease - A Promising Natural Molecule or Fashion of the Day? - A Narrowed Review.
Cholinesterase targeting by polyphenols: A therapeutic approach for the treatment of Alzheimer's disease.
Cholinesterase-responsive supramolecular vesicle.
Cholinesterases in cerebrospinal fluid. Correlations with clinical measures in Alzheimer's disease.
Cholinesterases in the amyloid angiopathy of Alzheimer's disease.
Cholinesterases in the cerebrospinal fluid, plasma, and erythrocytes of patients with Alzheimer's disease.
Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease.
Cholinesterases: new roles in brain function and in Alzheimer's disease.
CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients.
CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease.
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease.
Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors.
Clinanthus microstephus, an Amaryllidaceae species with cholinesterase inhibitor alkaloids: structure-activity analysis of haemanthamine skeleton derivatives.
Clinical and analytical considerations in the utilization of cholinesterase measurements.
Clinical Compliance of Donepezil in Treating Alzheimer's Disease in Taiwan.
Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors.
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
Clinical trials and therapy.
Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists.
Clinicopathological correlations and cholinesterase expression in early-onset familial Alzheimer's disease with the presenilin 1 mutation, Leu235Pro.
Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
Cochrane review on 'Statins for the treatment of dementia'
Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.
Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.
Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study.
Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
Cognitive pharmacotherapy of Alzheimer's disease and other dementias.
Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors.
Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics.
Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
Combination therapy for early Alzheimer's disease: what are we waiting for?
Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis.
Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.
Combined in Vitro and in Silico Studies for the Anticholinesterase Activity and Pharmacokinetics of Coumarinyl Thiazoles and Oxadiazoles.
Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice.
Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease.
Combining antioxidant astaxantin and cholinesterase inhibitor huperzine A boosts neuroprotection.
Comparative chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from Polygonum hydropiper L: a preliminary anti- Alzheimer's study.
Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice.
Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
Comparative Study of Chemical Composition, Cholinesterase Inhibition and Antioxidant Potential of Mentha pulegium L. Essential Oil.
Comparative study of selective in vitro and in silico BACE1 inhibitory potential of glycyrrhizin together with its metabolites, 18?- and 18?-glycyrrhetinic acid, isolated from Hizikia fusiformis.
Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors.
Comparison of cholinesterase inhibitor safety in real-world practice.
Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease.
Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects.
Comparison studies of cholinesterase inhibitors for Alzheimer's disease.
Competitive substrate inhibition in the histochemistry of cholinesterase activity in Alzheimer's disease.
Computational and experimental studies on the interaction between butyrylcholinesterase and fluoxetine: Implications in health and disease.
Computational and In-Vitro Validation of Natural Molecules as Potential Acetylcholinesterase Inhibitors and Neuroprotective Agents.
Computational and Kinetic Studies of Acetylcholine Esterase Inhibition by Phenserine.
Computational exploration and experimental validation to identify a dual inhibitor of cholinesterase and amyloid-beta for the treatment of Alzheimer's disease.
Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients.
Conjugates of ?-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease.
Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors.
Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile.
Continuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM).
Converting maslinic acid into an effective inhibitor of acylcholinesterases.
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.
Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study.
Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.
Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
Could the potential benefits of cholinesterase inhibitors in Alzheimer's disease be reduced after adjusting for coexisting diseases and multiple medications?
Coumarin, anthroquinone and stilbene derivatives with anticholinesterase activity.
Coumarins: Auspicious Cholinesterase and Monoamine Oxidase Inhibitors.
CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
CSF biomarkers predict a more malignant outcome in Alzheimer disease.
CSF cholinesterase in early-onset and late-onset Alzheimer's disease and multi-infarct dementia of Chinese patients.
Current and emerging pharmacological treatment options for dementia.
Current drugs and future hopes in the treatment of Alzheimer's disease.
Current issues in dementia pharmacotherapy.
Current smoking and response to cholinesterase inhibitor therapy in Alzheimer's disease.
Current Strategies and Novel Drug Approaches for Alzheimer Disease.
Current treatment of mild cognitive impairment and Alzheimer's disease.
Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Cyanobiphenyls: Novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer's disease.
Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease.
Deep cerebral microbleeds are associated with poor cholinesterase inhibitor treatment response in people with Alzheimer disease.
Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease.
Defining the role of the caregiver in Alzheimer's disease treatment.
Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.
Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Dementia with Lewy bodies: an emerging disease.
Dementia: epidemiology, intervention and concept of care.
Demonstrating the Role of Anticholinergic Activity in a Mood Disorder.
Desensitization of neuronal nicotinic receptors.
Desensitized nicotinic receptors in brain.
Design and development of novel p-aminobenzoic acid derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer's disease.
Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
Design, synthesis and biological evaluation of bambuterol analogues as novel inhibitors of butyrylcholinesterase.
Design, synthesis and biological evaluation of new 2-benzoxazolinone derivatives as potential cholinesterase inhibitors for therapy of alzheimer's disease.
Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors.
Design, synthesis and biological evaluation of novel deoxyvasicinone-indole as multi-target agents for Alzheimer's disease.
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Design, synthesis and biological evaluation of tacrine-1,2,3-triazole derivatives as potent cholinesterase inhibitors.
Design, synthesis and evaluation of dihydropyranoindole derivatives as potential cholinesterase inhibitors against Alzheimer's disease.
Design, synthesis and evaluation of novel cinnamic acid derivatives bearing N-benzyl pyridinium moiety as multifunctional cholinesterase inhibitors for Alzheimer's disease.
Design, synthesis and evaluation of novel indandione derivatives as multifunctional agents with cholinesterase inhibition, anti-?-amyloid aggregation, antioxidant and neuroprotection properties against Alzheimer's disease.
Design, synthesis and evaluation of novel tacrine-(?-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
Design, Synthesis, and Biological Evaluation of 1-Benzylamino-2-hydroxyalkyl Derivatives as New Potential Disease-Modifying Multifunctional Anti-Alzheimer's Agents.
Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors against Alzheimer's Diseases.
Design, Synthesis, and In Vitro Biological Activities of a Bio-Oxidizable Prodrug to Deliver Both ChEs and DYRK1A Inhibitors for AD Therapy.
Design, synthesis, in vivo and in vitro studies of 1,2,3,4-tetrahydro-9H-carbazole derivatives, highly selective and potent butyrylcholinesterase inhibitors.
Design, synthesis, in vitro and in vivo evaluation of benzylpiperidine-linked 1,3-dimethylbenzimidazolinones as cholinesterase inhibitors against Alzheimer's disease.
Design, synthesis, molecular docking, and cholinesterase inhibitory potential of phthalimide-dithiocarbamate hybrids as new agents for treatment of Alzheimer's disease.
Design, synthesis, molecular modeling and neuroprotective effects of a new framework of cholinesterase inhibitors for Alzheimer's disease.
Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Development and validation of a capillary zone electrophoretic method for rapid and sensitive determination of galanthamine: Application in plant and pharmaceuticals.
Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles.
Development of acetophenone ligands as potential neuroimaging agents for cholinesterases.
Development of donepezil-induced hypokalemia following treatment of cognitive impairment.
Development of HuperTacrines as Non-Toxic, Cholinesterase Inhibitors for the Potential Treatment of Alzheimer's Disease.
Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes.
Diabetes in a Large Dementia Cohort: Clinical Characteristics and Treatment From the Swedish Dementia Registry.
Diagnosis and management of Alzheimer disease.
Diagnosis and treatment of Alzheimer's disease.
Diagnosis and treatment of cognitive impairment.
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Differential blockade by huperzine A and donepezil of sympathetic nicotinic acetylcholine receptor-mediated nitrergic neurogenic dilations in porcine basilar arteries.
Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.
Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus.
Differential effects of donepezil on methamphetamine and cocaine dependencies.
Differential laminar distribution of acetylcholinesterase and butyrylcholinesterase containing tangles in the cerebral cortex of Alzheimer's disease.
Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo.
Differentiated cerebrovascular effects of physostigmine and tacrine in cortical areas deafferented from the nucleus basalis magnocellularis suggest involvement of basalocortical projections to microvessels.
Differentiation Between Dementia With Lewy Bodies And Alzheimer's Disease Using Voxel-Based Morphometry Of Structural MRI: A Multicenter Study.
Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology.
Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.
Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice.
Discontinuation, efficacy and safety of cholinesterase inhibitors for Alzheimer's disease: a meta-analysis and meta-regression of 44 randomized clinical trials enrolling 16,245 patients.
Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts.
Discorhabdin alkaloids from Antarctic Latrunculia spp. sponges as a new class of cholinesterase inhibitors.
Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.
Discovery of 9-phenylacridinediones as highly selective butyrylcholinesterase inhibitors through structure-based virtual screening.
Discovery of Butyrylcholinesterase-Activated Near-Infrared Fluorogenic Probe for Live-Cell and In Vivo Imaging.
Discovery of drug-like acetylcholinesterase inhibitors by rapid virtual screening of a 6.9 million compound database.
Discovery of Highly Selective and Nanomolar Carbamate-Based Butyrylcholinesterase Inhibitors by Rational Investigation into Their Inhibition Mode.
Discovery of isoalloxazine derivatives as a new class of potential anti-Alzheimer agents and their synthesis.
Discovery of new butyrylcholinesterase inhibitors via structure-based virtual screening.
Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
Discovery of potent and selective butyrylcholinesterase inhibitors through the use of pharmacophore-based screening.
Discovery of sustainable drugs for Alzheimer's disease: cardanol-derived cholinesterase inhibitors with antioxidant and anti-amyloid properties.
Discovery, biological evaluation and molecular dynamic simulations of butyrylcholinesterase inhibitors through structure-based pharmacophore virtual screening.
Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor.
Disease stage in Alzheimer disease and treatment effects of rivastigmine.
Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation.
Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies-an immunohistochemical study.
DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice.
Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? A preliminary report.
Do Cholinesterase Inhibitors Act Primarily on Attention Deficit? A Naturalistic Study in Alzheimer's Disease Patients.
Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
Donepezil and life expectancy in Alzheimer's disease: A retrospective analysis in the Tajiri Project.
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Donepezil and Rivastigmine: Pharmacokinetic Profile and Brain-targeting After Intramuscular Administration in Rats.
Donepezil blocks voltage-gated ion channels in rat dissociated hippocampal neurons.
Donepezil dosing strategies: pharmacokinetic considerations.
Donepezil Effects on Hippocampal and Prefrontal Functional Connectivity in Alzheimer's Disease: Preliminary Report.
Donepezil for Alzheimer's disease.
Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation.
Donepezil in low micromolar concentrations modulates voltage-gated potassium currents in pyramidal neurons of rat hippocampus.
Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
Donepezil in the treatment of patients with Alzheimer's disease.
Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain.
Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones.
Donepezil overdose: a tenfold dosing error.
Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients.
Donepezil use for advanced Alzheimer's disease--a case study from a long-term care facility.
Donepezil use in Alzheimer disease.
Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.
Donepezil, a cholinesterase inhibitor used in Alzheimer's disease therapy, is actively exported out of the brain by abcb1ab p-glycoproteins in mice.
Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease.
Donepezil-induced cervical dystonia in Alzheimer's disease: a case report and literature review of dystonia due to cholinesterase inhibitors.
Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys.
Donepezil-related toxic hepatitis.
Donepezil: potential neuroprotective and disease-modifying effects.
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application.
Double-blind placebo-controlled study of velnacrine in Alzheimer's disease.
Drug Design of Inhibitors of Alzheimer's Disease (AD): POM and DFT Analyses of Cholinesterase Inhibitory Activity of ?-amino di-Carbonyl Derivatives.
Drug interactions with cholinesterase inhibitors.
Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.
Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.
Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease.
Drug-induced urinary incontinence.
Drugs and falls in community-dwelling older people: a national veterans study.
Drugs for Alzheimer's disease. Guidelines for prescribing cholinesterase inhibitors in Australia are similar to those in UK.
Drugs for Alzheimer's disease: best avoided. No therapeutic advantage.
Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives.
Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.
Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease.
Dual monoamine oxidase and cholinesterase Inhibitors with different heterocyclic scaffolds.
Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs.
Duration of therapy with acetylcholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease as reported in the literature.
Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.
Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.
Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease.
Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?
Effect of APOE and CHRNA7 Genotypes on the Cognitive Response to Cholinesterase Inhibitor Treatment at Different Stages of Alzheimer's Disease.
Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.
Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Effect of cholinesterase inhibitors on attention.
Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease.
Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.
Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice.
Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats.
Effect of galantamine on platelet functions in healthy elderly people.
Effect of genetic polymorphisms on Alzheimer's disease treatment outcomes: an update.
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Effect of in vivo microdialysis of 1,2,3,4-tetrahydro-9-aminoacridine (THA) on the extracellular concentration of acetylcholine in the striatum of anesthetized rats.
Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia.
Effect of MDL 73,745 on acetylcholine and biogenic amine levels in rat cortex.
Effect of neostigmine on the hippocampal noradrenaline release: role of cholinergic receptors.
Effect of QT Prolongation in Patients Taking Cholinesterase Inhibitors (Donepezil) for Alzheimer's Disease.
Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer's disease.
Effect of rivastigmine on regional cerebral blood flow in Alzheimer's disease.
Effect of Rivastigmine or Memantine Add-on Therapy Is Affected by Butyrylcholinesterase Genotype in Patients with Probable Alzheimer's Disease.
Effective pharmacologic management of Alzheimer's disease.
Effective treatment of Alzheimer disease and its complications.
Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice.
Effectiveness of donepezil, rivastigmine and ({+/-})huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: Comparison with galantamine.
Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review.
Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease.
Effects of cholinesterase inhibitor on brain activation in Alzheimer's patients measured with functional near-infrared spectroscopy.
Effects of cholinesterase inhibitors and clonidine coadministration on rat cortex neurotransmitters in vivo.
Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy.
Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease: a systematic review.
Effects of Cholinesterase Inhibitors on the Activities and Protein Levels of Cholinesterases in the Cerebrospinal Fluid of Patients with Alzheimer's Disease: A Review of Recent Clinical Studies.
Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies.
Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures.
Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease.
Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients.
Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.
Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.
Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study.
Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: Data from the ICTUS study.
Effects of metrifonate on impairment of learning and dysfunction of cholinergic neuronal system in basal forebrain-lesioned rats.
Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats-Is there a potential for Alzheimer's disease treatment?
Effects of rivastigmine and memantine alone and in combination on learning and memory in rats with scopolamine-induced amnesia.
Effects of simultaneous administration of desferrioxamine and tacrine in rats.
Effects of simvastatin on malondialdehyde level and esterase activity in plasma and tissue of normolipidemic rats.
Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells.
Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats.
Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease.
Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease.
Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.
Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease.
Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence.
Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.
Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients.
Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan.
EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.
Electrocardiogram Changes of Donepezil Administration in Elderly Patients with Ischemic Heart Disease.
Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease.
Emerging links between type 2 diabetes and Alzheimer's disease.
Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease.
Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys.
Enhancement of Fear Extinction Memory and Resistance to Age-Related Cognitive Decline in Butyrylcholinesterase Knockout Mice and (R)-Bambuterol Treated Mice.
Ensemble Molecular Dynamics of a Protein-Ligand Complex: Residual Inhibitor Entropy Enhances Drug Potency in Butyrylcholinesterase.
Established donepezil treatment modulates task relevant regional brain activation in early Alzheimer's disease.
Estimation of neuroprotective effects of Laurocerasus officinalis Roem. (cherry laurel) by in vitro methods
Estimation of plasma tacrine concentrations using an in vitro cholinesterase inhibition assay.
Evaluating Fmoc-amino acids as selective inhibitors of butyrylcholinesterase.
Evaluating the Memory Enhancing Effects of Angelica gigas in Mouse Models of Mild Cognitive Impairments.
Evaluation of Anticholinesterase and Inflammation Inhibitory Activity of Medicinal Mushroom Phellinus pini (Basidiomycetes) Fruiting Bodies.
Evaluation of blood-brain barrier and blood-cerebrospinal fluid barrier permeability of 2-phenoxy-indan-1-one derivatives using in vitro cell models.
Evaluation of butyrylcholinesterase inhibitory activity by chlorogenic acids and coffee extracts assed in ITC and docking simulation models.
Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease.
Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches.
Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease.
Evaluation of salivary acetylcholinesterase and pseudocholinesterase in patients with Alzheimer's disease: A case-control study.
Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease.
Evaluation of the neuroprotective and antidiabetic potential of phenol-rich extracts from virgin olive oils by in vitro assays.
Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
Evidence-based pharmacotherapy of Alzheimer's disease.
Expansion of the scaffold diversity for the development of highly selective butyrylcholinesterase (BChE) inhibitors: Discovery of new hits through the pharmacophore model generation, virtual screening and molecular dynamics simulation.
Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors.
Exploring the halophyte Cistanche phelypaea (L.) Cout as a source of health promoting products: In vitro antioxidant and enzyme inhibitory properties, metabolomic profile and computational studies.
Facile synthesis of new carbon-11 labeled conformationally restricted rivastigmine analogues as potential PET agents for imaging AChE and BChE enzymes.
Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting.
Factors associated with use of medications with potential to impair cognition or cholinesterase inhibitors among Alzheimer's disease patients.
Failure to confirm a synergistic effect between the K-variant of the butyrylcholinesterase gene and the epsilon4 allele of the apolipoprotein gene in Japanese patients with Alzheimer's disease.
Fatal aspiration pneumonia during transition from donepezil to rivastigmine.
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents.
FDA approves new cholinesterase inhibitor for Alzheimer's disease.
First-in-Class Isonipecotamide-Based Thrombin and Cholinesterase Dual Inhibitors with Potential for Alzheimer Disease.
Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy.
Focus on the Correlations between Alzheimer's Disease and Type 2 Diabetes.
Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people.
For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not?
Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex.
Four new mutations in the BCHE gene of human butyrylcholinesterase in a Brazilian blood donor sample.
From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
From molecular structure to Alzheimer therapy.
From toxic precursors to safe drugs. Mechanisms and relevance of idiosyncratic drug reactions.
Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease.
Functional and subcellular organelle changes in isolated rat and human hepatocytes induced by tetrahydroaminoacridine.
Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease.
Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease.
Galantamine blocks cloned Kv2.1, but not Kv1.5 potassium channels.
Galantamine for vascular cognitive impairment.
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.
Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease.
Galantamine-based hybrid molecules with acetylcholinesterase, butyrylcholinesterase and ?-secretase inhibition activities.
Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.
Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[ (18)F]Fluoro-A-85380 PET.
Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.
Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats.
GC/MS Analysis of Alkaloids in Galanthus fosteri Baker and Determination of Its Anticholinesterase Activity.
Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study.
Gender-related differences in circadian rhythm of rat plasma acetyl- and butyrylcholinesterase: Effects of sex hormone withdrawal.
Gene-gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer's disease risk.
Genoprotective and neuroprotective effects of Daphne gnidium leaf methanol extract, tested on male mice.
Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
Good rate of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease after three months of treatment: An open-label study.
Growth Hormone Responses to Low-Dose Physostigmine in Elderly vs. Young Women and Men.
Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.
Hemodynamic effects of cholinesterase inhibition in mild Alzheimer's disease.
High Expression Level of Antioxidants and Pharmaceutical Bioactivities of Endophytic Fungus Chaetomium Globosum JN711454.
High-performance liquid chromatography with fast-scanning fluorescence detection and multivariate curve resolution for the efficient determination of galantamine and its main metabolites in serum.
Higher levels of thyroxine may predict a favorable response to donepezil treatment in patients with Alzheimer disease: a prospective, case-control study.
Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease.
Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection.
Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease.
Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer's Disease Mouse Model.
Hippocampal atrophy but not white-matter changes predicts the long-term cognitive response to cholinesterase inhibitors in Alzheimer's disease.
Homozygosity for the K variant of BCHE gene increases the risk for development of neurofibrillary pathology but not amyloid deposits at young ages.
Honey as the Potential Natural Source of Cholinesterase Inhibitors in Alzheimer's Disease.
How Prolific is Psychotropic Medicines Use in People with Dementia in Australia Within the Community Setting? A Retrospective Analysis.
How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis.
HPLC-MS/MS chemical characterization and biological properties of Origanum onites extracts: a recent insight.
Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro.
Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease.
Identification and molecular docking study of fish roe-derived peptides as potent BACE 1, AChE, and BChE inhibitors.
Identification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of Huperzine A.
Identification of the urinary metabolites of tacrine in the rat.
Imaging butyrylcholinesterase activity in Alzheimer's disease.
Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's disease.
Immobilized cholinesterases capillary reactors on-flow screening of selective inhibitors.
Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.
Immunomodulation by 9-amino-1,2,3,4-tetrahydroacridine (THA): 1. Down-regulation of natural cell-mediated cytotoxicity in vitro.
Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease.
Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.
Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study.
Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease.
Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia.
Impaired spatial learning and suppression of sharp wave ripples by cholinergic activation at the goal location.
Implementation of the Pharmacists' Patient Care Process in a Medicinal Chemistry Course.
Implications of some selected flavonoids towards Alzheimer's disease with the emphasis on cholinesterase inhibition and their bioproduction by metabolic engineering.
Important error in 'systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias' by muayqil and camicioli.
In silico ligand-receptor docking of potentially selective butyrylcholinesterase inhibitors structurally related to the marine natural product debromoflustramine B.
In silico modeling for dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes in Alzheimer's disease.
In silico modeling of the specific inhibitory potential of thiophene-2,3-dihydro-1,5-benzothiazepine against BChE in the formation of beta-amyloid plaques associated with Alzheimer's disease.
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
In silico, theoretical biointerface analysis and in vitro kinetic analysis of amine compounds interaction with acetylcholinesterase and butyrylcholinesterase.
IN VITRO ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE INHIBITORY POTENTIALS OF JATROPHA GOSSYPIFOLIA PLANT EXTRACTS.
In vitro and in silico analysis of novel astaxanthin-s-allyl cysteine as an inhibitor of butyrylcholinesterase and various globular forms of acetylcholinesterases.
In vitro and in vivo metabolism and inhibitory activities of vasicine, a potent acetylcholinesterase and butyrylcholinesterase inhibitor.
In vitro anticholinesterase, antimonoamine oxidase and antioxidant properties of alkaloid extracts from kola nuts (Cola acuminata and Cola nitida).
In vitro antioxidant and cholinesterase inhibitory activities of Elatostema papillosum leaves and correlation with their phytochemical profiles: a study relevant to the treatment of Alzheimer's disease.
In Vitro Antioxidant, Anti-Diabetes, Anti-Dementia, and Inflammation Inhibitory Effect of Trametes pubescens Fruiting Body Extracts.
In vitro metabolism of BYZX in human liver microsomes and the structural elucidation of metabolite by liquid chromatography-mass spectrometry method.
In vitro neuroprotective effects of the leaf and fruit extracts of Juglans regia L. (walnut) through enzymes linked to Alzheimer's disease and antioxidant activity.
In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048.
In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Inactivation of cholinesterase induced by non-steroidal anti-inflammatory drugs with horseradish peroxidase: implication for Alzheimer's disease.
Increase in Platelet Immunoglobulin in Alzheimer's Disease is Lowered Following Cholinesterase Inhibitor Treatment: Preliminary Results.
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.
Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists.
Increasing rational use of cholinesterase inhibitors for Alzheimer's disease in Brazil: public health strategy combining guideline with peer-review of prescriptions.
Individualized evaluation of cholinesterase inhibitors effects in dementia with adaptive cognitive testing.
Indole alkaloids from Ervatamia hainanensis with potent acetylcholinesterase inhibition activities.
Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis.
Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.
Influence of different extraction techniques on the chemical profile and biological properties of Anthemis cotula L.: Multifunctional aspects for potential pharmaceutical applications.
Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease.
Influence of tacrine on dopamine-induced reactions of the gastric smooth muscle of rats.
Inhibition of ?-site amyloid precursor protein cleaving enzyme 1 and cholinesterases by pterosins via a specific structure-activity relationship with a strong BBB permeability.
Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Inhibition of acetylcholinesterase and butyrylcholinesterase with uracil derivatives: kinetic and computational studies.
Inhibition of cholinesterase by essential oil from food plant.
Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.
Inhibition of murine cytochrome P4501A by tacrine: in vitro studies.
Inhibition of two different cholinesterases by tacrine.
Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats.
Inhibitory evaluation of oligonol on ?-glucosidase, protein tyrosine phosphatase 1B, cholinesterase, and ?-secretase 1 related to diabetes and Alzheimer's disease.
Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease.
Initiating and monitoring cholinesterase inhibitor treatment for Alzheimer's disease.
Innovations: geriatric psychiatry: diagnosis and treatment of neuropsychiatric symptoms in Alzheimer's disease.
Interaction between Apolipoprotein E and Butyrylcholinesterase Genes on Risk of Alzheimer's Disease in a Prospective Cohort Study.
Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk.
Interaction between estrogen receptor-alpha and butyrylcholinesterase genes modulates Alzheimer's disease risk.
Interaction of Exogenous Butyrylcholinesterase with ?-Amyloid Plaques in 5XFAD/Butyrylcholinesterase-Knockout Mouse Brain.
Intra-operative bradycardia in a patient with Alzheimer's disease treated with two cholinesterase inhibitors.
Investigating 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole as scaffold of butyrylcholinesterase-selective inhibitors with additional neuroprotective activities for Alzheimer's disease.
Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer's disease.
Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications.
Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline.
Is Combining an Anticholinergic with a Cholinesterase Inhibitor a Good Strategy for High-Level CNS Cholinesterase Inhibition?
Is donepezil therapy associated with reduced mortality in nursing home residents with dementia?
Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?
Is rivastigmine safe as pretreatment against nerve agents poisoning? A pharmacological, physiological and cognitive assessment in healthy young adult volunteers.
Is the risk of developing Alzheimer's disease really higher in rural areas? A multilevel longitudinal study of 261,669 Australians aged 45 years and older tracked over 11 years.
Isocorilagin, a cholinesterase inhibitor from Phyllanthus niruri.
Isolation, crystal structure determination and cholinesterase inhibitory potential of isotalatizidine hydrate from Delphinium denudatum.
Isolation, identification, and quantification of Pentylcurcumene from Geophila repens: A new class of cholinesterase inhibitor for Alzheimer's disease.
Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability.
Isothiocyanates: cholinesterase inhibiting, antioxidant, and anti-inflammatory activity.
Isoxazolotacrines as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer's disease.
Juliflorine: a potent natural peripheral anionic-site-binding inhibitor of acetylcholinesterase with calcium-channel blocking potential, a leading candidate for Alzheimer's disease therapy.
Kinetics and computational analysis of cholinesterase inhibition by REVERC3, a bisdemethoxycurcumin-rich Curcuma longa extract: Relevance to the treatment of Alzheimer's disease.
Kinetics and molecular docking studies of loganin, morroniside and 7-O-galloyl-D-sedoheptulose derived from Corni fructus as cholinesterase and ?-secretase 1 inhibitors.
Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
Kinetics of Torpedo californica Acetylcholinesterase Inhibition by Bisnorcymserine and Crystal Structure of the Complex with its Leaving Group.
Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
Large-scale studies of the functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes and insulin secretion.
Left frontal lobe hypoperfusion and depressive symptoms in Alzheimer's disease patients taking cholinesterase inhibitors.
Lending a helping eye: artists in residence at a memory clinic.
Lepidine B from Lepidium Sativum Seeds as Multi-Functional Anti-Alzheimer's Disease Agent: In Vitro and In Silico Studies.
Lifestyle improvement or anti-dementia drugs in Alzheimer's disease: A comment on Kapaki et al. The cognitive effects of cholinesterase inhibitor treatment in every-day practice. Curr Med Res Opin 2005; 21(6): 871-5.
Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease.
Long-term cholinesterase inhibitor therapy for Alzheimer's disease: implications for long-term care.
Long-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care Physician.
Long-term cholinesterase inhibitor treatment of Alzheimer's disease.
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
Long-term effect of galantamine on cognitive function in patients with Alzheimer's disease versus a simulated disease trajectory: an observational study in the clinical setting.
Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer's disease.
Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.
Long-term Outcome and Prediction Models of Activities of Daily Living in Alzheimer Disease With Cholinesterase Inhibitor Treatment.
Long-Term Response to Cholinesterase Inhibitor Treatment Is Related to Functional MRI Response in Alzheimer's Disease.
Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services.
Longitudinal evaluation of a novel BChE PET tracer as an early in vivo biomarker in the brain of a mouse model for Alzheimer disease.
Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.
Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease.
Low Plasma Cholinesterase Activities are Associated with Deficits in Spatial Orientation, Reduced Ability to Perform Basic Activities of Daily Living, and Low Body Mass Index in Patients with Progressed Alzheimer's Disease.
M1 agonists as a potential disease-modifying therapy for Alzheimer's disease.
Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy.
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Mechanism of action of cholinesterase inhibitors in Alzheimer's disease.
Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease.
Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model.
Melatonin as a structural template in the development of novel drugs for neurodegenerative disorders.
Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review.
Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.
Memantine combined with an acetyl cholinesterase inhibitor - hope for the future?
Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors.
Memantine for the treatment of dementia.
Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy.
Memantine treatment for Japanese patients with moderate to severe Alzheimer's disease: a meta-analysis of double-blind, randomized, placebo-controlled trials.
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease.
Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.
Memory loss.
Mesial Frontal Lobe Infarction Presenting as Pisa Syndrome.
Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
Metabolite Profiling by Hyphenated Liquid Chromatographic Mass Spectrometric Technique (HPLC-DAD-ESI-Q-TOF-MS/MS) and Neurobiological Potential of Haplophyllum sahinii and H. vulcanicum Extracts.
Methanesulfonyl fluoride (MSF) blocks scopolamine-induced amnesia in rats.
Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease.
Metrifonate and tacrine: a comparative study on their effect on acetylcholine dynamics in mouse brain.
Metrifonate decreases sI(AHP) in CA1 pyramidal neurons in vitro.
Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
Metrifonate treatment enhances acquisition of eyeblink conditioning in aging rabbits.
Metrifonate: a new agent for the treatment of Alzheimer's disease.
Metrifonate: update on a new antidementia agent.
Microwave-assisted synthesis of novel purine nucleosides as selective cholinesterase inhibitors.
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
Modulation of brain acetylcholine levels with cholinesterase inhibitors as a treatment of Alzheimer disease.
Modulation of cholinergic transmission enhances excitability of hippocampal pyramidal neurons and ameliorates learning impairments in aging animals.
Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory.
Modulation of N-methyl-D-aspartate receptors by donepezil in rat cortical neurons.
Modulatory effect of caffeic acid on cholinesterases inhibitory properties of donepezil.
Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
Molecular design and synthesis of novel peptides from amphibians skin acting as inhibitors of cholinesterase enzymes.
Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and ?-amyloid inhibitors for Alzheimer's disease.
Molecular Dynamics Revealing a Detour-Forward Release Mechanism of Tacrine: Implication for the Specific Binding Characteristics in Butyrylcholinesterase.
Molecular forms of cholinesterases in CSF of Alzheimer's disease/senile dementia of Alzheimer type patients and matched neurological controls.
Molecular modeling and in vitro approaches towards cholinesterase inhibitory effect of some natural xanthohumol, naringenin, and acyl phloroglucinol derivatives.
Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.
Multi-target approach for Alzheimer's disease treatment: computational biomolecular modeling of cholinesterase enzymes with a novel 4-N-phenylaminoquinoline derivative reveal promising potentials.
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
Multifunctional Activity of Polyphenolic Compounds Associated with a Potential for Alzheimer's Disease Therapy from Ecklonia cava.
Multifunctional cholinesterase inhibitors for Alzheimer's disease: Synthesis, biological evaluations, and docking studies of o/p-propoxyphenylsubstituted-1H-benzimidazole derivatives.
Multifunctional Donepezil Analogues as Cholinesterase and BACE1 Inhibitors.
Multifunctional tacrine-flavonoid hybrids with cholinergic, ?-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease.
Multiple actions of THA on cholinergic neurotransmission in Alzheimer brains.
Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.
Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.
Multitarget therapeutic strategies for Alzheimer's disease.
Muscarinic, Ca(++) antagonist and specific butyrylcholinesterase inhibitory activity of dried ginger extract might explain its use in dementia.
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
N-[18F]fluoroethylpiperidin-4-ylmethyl butyrate: a novel radiotracer for quantifying brain butyrylcholinesterase activity by positron emission tomography.
Natural cholinesterase inhibitors from marine organisms.
Neither the butyrylcholinesterase K variant nor transferrin C2 variant confers a risk for Alzheimer's disease in Koreans.
Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease.
Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.
Neuropharmacological effect of Mangiferin on brain cholinesterase and brain biogenic amines in the management of Alzheimer's disease.
Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease.
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and ?-amyloid in aging and Alzheimer's disease.
Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.
Neuroprotective Potential of Novel Multi-Targeted Isoalloxazine Derivatives in Rodent Models of Alzheimer's Disease Through Activation of Canonical Wnt/?-Catenin Signalling Pathway.
Neuroprotective Role of Novel Triazine Derivatives by Activating Wnt/? Catenin Signaling Pathway in Rodent Models of Alzheimer's Disease.
Neuropsychological rehabilitation program and behavioral disturbances in early-stage Alzheimer patients.
Neurotransmitter Imbalance in the Brain and Alzheimer's Disease Pathology.
New (benz)imidazolopyridino tacrines as nonhepatotoxic, cholinesterase inhibitors for Alzheimer disease.
New 4-N-phenylaminoquinoline derivatives as antioxidant, metal chelating and cholinesterase inhibitors for Alzheimer's disease.
New anthrarobin acyl derivatives as butyrylcholinesterase inhibitors: synthesis, in vitro and in silico studies.
New cholinesterase inhibitors for Alzheimer's disease: Structure activity relationship, kinetics and molecular docking studies of 1-butanoyl-3-arylthiourea derivatives.
New cholinesterase inhibitors for Alzheimer's disease: Structure Activity Studies (SARs) and molecular docking of isoquinolone and azepanone derivatives.
New Drug Research and Development for Alzheimer's Pathology: Present and Prospect.
New drugs for Alzheimer's disease.
New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition.
New Hybrids of 4-Amino-2,3-polymethylene-quinoline and p-Tolylsulfonamide as Dual Inhibitors of Acetyl- and Butyrylcholinesterase and Potential Multifunctional Agents for Alzheimer's Disease Treatment.
New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.
New pharmacological strategies for cognitive enhancement using a rat model of age-related memory impairment.
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
New trends in cholinergic therapy for Alzheimer disease: nicotinic agonists or cholinesterase inhibitors?
Newly developed drugs for Alzheimer's disease in relation to energy metabolism, cholinergic and monoaminergic neurotransmission.
NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?
Nicotine and sensory memory in Alzheimer's disease: an event-related potential study.
Nicotinic autoreceptors mediating enhancement of acetylcholine release become operative in conditions of "impaired" cholinergic presynaptic function.
No association between butyrylcholinesterase K-variant and Alzheimer disease in Chinese.
No association between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease.
No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease.
No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases.
No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model.
Non-anticholinesterase, non-cholinergic effect of tacrine on gastrointestinal smooth muscle tissues of rat.
Non-cholinergic strategies for treating and preventing Alzheimer's disease.
Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease.
Nontoxic and neuroprotective ?-naphthotacrines for Alzheimer's disease.
Nose-to-brain delivery of tacrine.
Novel 2-pheynlbenzofuran derivatives as selective butyrylcholinesterase inhibitors for Alzheimer's disease.
Novel AChE and BChE Inhibitors Using Combined Virtual Screening, Text mining and In Vitro Binding Assays.
Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
Novel carbamate derivatives as selective butyrylcholinesterase inhibitors.
Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease.
Novel inhibitors with sulfamethazine backbone: synthesis and biological study of multi-target cholinesterases and ?-glucosidase inhibitors.
Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation.
Novel N-benzylpiperidine carboxamide derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer's disease.
Novel pyridazinone derivatives as butyrylcholinesterase inhibitors.
Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease.
Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer's Disease.
Novel tacrine analogs as potential cholinesterase inhibitors in Alzheimer's disease.
Novel tacrine-coumarin hybrids linked to 1,2,3-triazole as anti-Alzheimer's compounds: In vitro and in vivo biological evaluation and docking study.
Novel tetrahydrocarbazole benzyl pyridine hybrids as potent and selective butryl cholinesterase inhibitors with neuroprotective and ?-secretase inhibition activities.
Nutraceutical Potential of Phenolics from 'Brava' and 'Mansa' Extra-Virgin Olive Oils on the Inhibition of Enzymes Associated to Neurodegenerative Disorders in Comparison with Those of 'Picual' and 'Cornicabra'.
Odor Identification Impairment and Change with Cholinesterase Inhibitor Treatment in Mild Cognitive Impairment.
Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease.
Older patients are still under-represented in clinical trials of Alzheimer's disease.
Omega-3 Fatty Acids Increase Amyloid-? Immunity, Energy, and Circadian Rhythm for Cognitive Protection of Alzheimer's Disease Patients Beyond Cholinesterase Inhibitors.
On the active site for hydrolysis of aryl amides and choline esters by human cholinesterases.
Oral donepezil reduces hypersensitivity after nerve injury by a spinal muscarinic receptor mechanism.
Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease.
Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease.
Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors.
Outlining In Vitro and In Silico Cholinesterase Inhibitory Activity of Twenty-Four Natural Products of Various Chemical Classes: Smilagenin, Kokusaginine, and Methyl Rosmarinate as Emboldening Inhibitors.
Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer's disease: a case-control study.
Parkinson's disease dementia: clinical correlates of brain spect perfusion and treatment.
Patient and caregiver outcomes after 6 +/- 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study.
Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Pelargonidin improves memory deficit in amyloid ?25-35 rat model of Alzheimer's disease by inhibition of glial activation, cholinesterase, and oxidative stress.
Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine.
Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer's disease.
Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
Persistence with cholinesterase inhibitor treatment in Alzheimer's disease.
Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer's disease (AD).
Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
Pharmaco-EEG test dose response predicts cholinesterase inhibitor treatment outcome in Alzheimer's disease.
Pharmacodynamic and early clinical studies with velnacrine.
Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects.
Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.
Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.
Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimer's Disease Pharmacogenetics.
Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.
Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease.
Pharmacogenomics and therapeutic prospects in Alzheimer's disease.
Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors.
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
Pharmacokinetic rationale for the rivastigmine patch.
Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.
Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease.
Pharmacokinetics and pharmacodynamics of metrifonate in humans.
Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.
Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers.
Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species.
Pharmacokinetics, excretion and metabolites analysis of DL0410, a dual?acting cholinesterase inhibitor and histamine?3 receptor antagonist.
Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
Pharmacological basis of drug therapy of Alzheimer's disease.
Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people.
Pharmacological Evaluation and Docking Studies of 3-Thiadiazolyl- and Thioxo-1,2,4-triazolylcoumarin Derivatives as Cholinesterase Inhibitors.
Pharmacological strategies for the prevention of Alzheimer's disease.
Pharmacological therapy for people with Alzheimer's disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs.
Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics.
Pharmacological treatment of cognitive deficits in Alzheimer's disease.
Pharmacology and clinical efficacy of cholinesterase inhibitors.
Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
Pharmacophore based 3DQSAR of phenothiazines as specific human butyrylcholinesterase inhibitors for treatment of Alzheimer's disease.
Pharmacophore-based drug design for the identification of novel butyrylcholinesterase inhibitors against Alzheimer's disease.
Pharmacophore-based virtual screening and molecular docking to identify promising dual inhibitors of human acetylcholinesterase and butyrylcholinesterase.
Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors.
Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine.
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
Phenolic Profiles, Antioxidant, and Inhibitory Activities of Kadsura heteroclita (Roxb.) Craib and Kadsura coccinea (Lem.) A.C. Sm.
Phthalimide-Derived N-Benzylpyridinium Halides Targeting Cholinesterases: Synthesis and Bioactivity of New Potential Anti-Alzheimer's Disease Agents.
Physicians' efficacy requirements for prescribing medications to persons with Alzheimer's disease*.
Physiological and neurobehavioral effects of cholinesterase inhibition in healthy adults.
Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain.
Phytochemical Analysis and Cholinesterase Inhibitory and Antioxidant Activities of Enhydra fluctuans Relevant in the Management of Alzheimer's Disease.
Phytochemical Analysis and Evaluation of Biological Activity of Lawsonia inermis Seeds Related to Alzheimer's Disease.
Phytochemical profile and anticholinesterase and antimicrobial activities of supercritical versus conventional extracts of Satureja montana.
Phytochemical profile of a blend of black chokeberry and lemon juice with cholinesterase inhibitory effect and antioxidant potential
Phytochemical profile of a blend of black chokeberry and lemon juice with cholinesterase inhibitory effect and antioxidant potential.
Phytomedicines as potential inhibitors of ? amyloid aggregation: significance to Alzheimer's disease.
Plant-Based Synthesis of Zinc Oxide Nanoparticles (ZnO-NPs) Using Aqueous Leaf Extract of Aquilegia pubiflora: Their Antiproliferative Activity against HepG2 Cells Inducing Reactive Oxygen Species and Other In Vitro Properties.
Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease.
Plasma butyrylcholinesterase activity: a possible biomarker for differential diagnosis between Alzheimer's disease and dementia with Lewy bodies?
Plasma catecholamine and cardiovascular responses to physostigmine in Alzheimer's disease and aging.
Plasma Cholinesterase Activity in Alzheimer's Disease.
Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer's disease.
Policy-induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia.
Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
Poststroke dementia in the elderly.
Potential alternatives to current cholinesterase inhibitors: an in silico drug repurposing approach.
Potential anti-cholinesterase and ?-site amyloid precursor protein cleaving enzyme 1 inhibitory activities of cornuside and gallotannins from Cornus officinalis fruits.
Potential for intermittent stimulation of nucleus basalis of Meynert to impact treatment of alzheimer's disease.
Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Potential Nutraceutical Properties of Leaves from Several Commonly Cultivated Plants.
Potential role for estrogen replacement in the treatment of Alzheimer's dementia.
Potentially inappropriate prescriptions of anticholinergics drugs in Alzheimer's disease patients.
Potentially procholinergic effects of medications commonly used in older adults.
Practical Principles for the Management of Alzheimer's Disease.
Pratensein attenuates A?-induced cognitive deficits in rats: Enhancement of synaptic plasticity and cholinergic function.
Precision medicine in Alzheimer's disease: An origami paper-based electrochemical device for cholinesterase inhibitors.
Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.
Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease.
Prediction models for assessing long-term outcome in Alzheimer's disease: a review.
Predictions of BuChE inhibitors using support vector machine and naive Bayesian classification techniques in drug discovery.
Predictive Factors of Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer's Disease and Mixed Dementia: A One-Year Naturalistic Study.
Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study.
Predictors of long-term cognitive outcome in Alzheimer's disease.
Predictors of long-term treatment effect of rivastigmine in Alzheimer's disease: a role for beta-amyloid plasma levels?
Predictors of Response to Cholinesterase Inhibitors Treatment of Alzheimer's Disease: Date Mining from the TREDEM Registry.
Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis.
Preliminary evidence that rivastigmine-induced inhibition of serum butyrylcholinesterase activity improves behavioral symptoms in Japanese patients with Alzheimer's disease.
Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles.
Prescribing Cholinesterase Inhibitors for Alzheimer Disease: Timing Matters.
Prescribing trends in cognition enhancing drugs in Australia.
Prescription patterns and efficacy of drugs for patients with dementia: physicians' perspective in Italy.
Present and future of Alzheimer therapy.
Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease.
Prevalence of positive carotid sinus massage and related risk of syncope in patients with Alzheimer's disease.
Preventing Alzheimer's disease : separating fact from fiction.
Preventive role of Indian black pepper in animal models of Alzheimer's disease.
Profiling Auspicious Butyrylcholinesterase Inhibitory Activity of Two Herbal Molecules: Hyperforin and Hyuganin C.
Progress in Alzheimer's disease drug discovery: an update.
Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias--review and comparison of the cholinesterase inhibitors.
Progress in drug development for Alzheimer's disease: An overview in relation to mitochondrial energy metabolism.
Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.
Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease.
Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
Prospective Application of Two New Pyridine-Based Zinc (II) Amide Carboxylate in Management of Alzheimer's Disease: Synthesis, Characterization, Computational and in vitro Approaches.
Protease inhibitors and indolamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer's disease.
Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease.
Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-?-amyloid aggregation and antioxidant properties for the treatment of Alzheimer's disease.
Pteryxin - A promising butyrylcholinesterase-inhibiting coumarin derivative from Mutellina purpurea.
Purification of Acetylcholinesterase by 9-Amino-1,2,3,4-tetrahydroacridine from Human Erythrocytes.
Pursuing the Complexity of Alzheimer's Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and N-Methyl-d-Aspartate Receptor Antagonists.
Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast ?-glucosidase, acetylcholinesterase and butyrylcholinesterase.
Quality of life and cholinesterase inhibitors: a qualitative study of patients with Alzheimer's Disease and their carers.
Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease.
Quantitative whole-body autoradiographic determination of tacrine tissue distribution in rats following intravenous or oral dose.
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
QuinoxalineTacrine QT78, a Cholinesterase Inhibitor as a Potential Ligand for Alzheimer's Disease Therapy.
Radiolabeled cholinesterase substrates: in vitro methods for determining structure-activity relationships and identification of a positron emission tomography radiopharmaceutical for in vivo measurement of butyrylcholinesterase activity.
Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients.
Rapid and sensitive detection of the inhibitive activities of acetyl- and butyryl-cholinesterases inhibitors by UPLC-ESI-MS/MS.
Rapid discovery of a selective butyrylcholinesterase inhibitor using structure-based virtual screening.
Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation.
Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis.
Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
Rational design of a drug for Alzheimer's disease with cholinesterase inhibitory and neuroprotective activity.
Rationale for transdermal drug administration in Alzheimer disease.
Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's.
Rationalizing therapeutic approaches in Alzheimer's disease.
RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?
rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine.
Re: Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease.
Reaching the population with dementia drugs: what are the challenges?
Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial.
Reassessment of the dementia diagnosis of Alzheimer's disease in patients enrolled on the cholinesterase inhibitors dispensation program.
Recent developments in tau-based therapeutics for neurodegenerative diseases.
Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease.
Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease.
Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease.
Regional brain activity after prolonged cholinergic enhancement in early Alzheimer's disease.
Regulators of cholinergic signaling in disorders of the central nervous system.
Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E epsilon 4 genes in early-onset coronary artery disease.
Relation between cholinesterase inhibitor and Pisa syndrome.
Relationship between cholinesterase inhibitors and Pisa syndrome in a cohort of five French patients with Alzheimer's disease.
Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
Relationship between Pisa syndrome and cholinesterase inhibitor use for elderly adults with Alzheimer's disease.
Relative tolerability of Alzheimer's disease treatments.
Removal of Drugs for Alzheimer's Disease from the List of Reimbursable Drugs in France: Analysis of Change in Drug Use, Disease Management and Cognition Using the National Alzheimer Data Bank (BNA).
Report of ten years' activity in an Alzheimer's disease assessment unit.
Reports in pharmacological treatments in geriatric psychiatry: is there anything new or just adding to old evidence?
Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor.
Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
Responders to ChEI treatment of Alzheimer's disease show restitution of normal regional cortical activation.
Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.
Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.
Response to letter from Garcia and colleagues on cholinesterase inhibitors and Alzheimer's disease outcomes.
Responses of hypothalamo-pituitary-adrenal axis to a cholinesterase inhibitor.
Responses to donepezil in Alzheimer's disease and Parkinson's disease.
Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene.
Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the "real world" (CRONOS project): a 36-week follow-up study.
Retrospective Study on the Benefits of Combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: The MEMAGE Study.
Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates.
Reversal of memory deficits by Coriandrum sativum leaves in mice.
Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report.
Review: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease.
Review: cholinesterase inhibitors may be effective in Alzheimer disease.
Review: Cholinesterase inhibitors may be effective in Alzheimer's disease.
Review: cholinesterase inhibitors reduce burden and care time for informal carers of people with Alzheimer's disease.
Risk Factors for Nursing Home Placement in Alzheimer's Disease: A Longitudinal Study of Cognition, ADL, Service Utilization, and Cholinesterase Inhibitor Treatment.
Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study.
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Rivastigmine for Alzheimer's disease.
Rivastigmine for vascular cognitive impairment.
Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.
Rivastigmine improves dual-task gait velocity in patients with Alzheimer's disease.
Rivastigmine in Alzheimer disease: efficacy over two years.
Rivastigmine in Parkinson's disease dementia.
Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
Rivastigmine modifies the ?-secretase pathway and potentially early Alzheimer's disease.
Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.
Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease.
Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis.
Role of Cholinesterase Inhibitors in Managing Behavioral Problems in Alzheimer's Disease.
Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer's disease.
Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.
Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study.
Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Savings from sub-groups?: policy guidance and Alzheimer's disease treatments.
Scocycamides, a Pair of Macrocyclic Dicaffeoylspermidines with Butyrylcholinesterase Inhibition and Antioxidation Activity from the Roots of Scopolia tangutica.
Scouting around 1,2,3,4-Tetrahydrochromeno[3,2-c]pyridin-10-ones for Single- and Multitarget Ligands Directed towards Relevant Alzheimer's Targets.
Screening and identification of secondary metabolites in the bark of Bauhinia variegata to treat Alzheimer's disease by using molecular docking and molecular dynamics simulations.
Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force.
Seizures in an Alzheimer's disease patient as a complication of colonoscopy premedication with meperidine.
Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce amyloid-? Ex Vivo Activation of Peripheral Chemo-Cytokines from Alzheimer's Disease Subjects: Exploring the Cholinergic Anti-Inflammatory Pathway.
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.
Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
Selective in vitro and in silico butyrylcholinesterase inhibitory activity of diterpenes and rosmarinic acid isolated from Perovskia atriplicifolia Benth. and Salvia glutinosa L.
Selective Pseudo-irreversible Butyrylcholinesterase Inhibitors Transferring Antioxidant Moieties to the Enzyme Show Pronounced Neuroprotective Efficacy In Vitro and In Vivo in an Alzheimer's Disease Mouse Model.
Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine.
Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.
Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.
Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease.
Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors.
Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.
Short- and long-term efficacy of cholinesterase inhibitors in older adults with alzheimer's disease and mixed dementia: results of a 21-month observational study.
Short-Term Response is not Predictive of Long-Term Response to Acetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer's Disease: A "Real World" Study.
Short-Term Response to Cholinesterase Inhibitors in Alzheimer's Disease Delays Time to Nursing Home Placement.
Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors.
Significant effects of cholinesterase inhibitors on tau pathology in the Alzheimer's disease continuum: An in vivo positron emission tomography study.
Simultaneous release of glutamate and acetylcholine from single magnocellular "cholinergic" basal forebrain neurons.
Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.
Spatial discrimination deficits by excitotoxic lesions in the Morris water escape task.
Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease.
Species- and concentration-dependent differences of Acetyl- and Butyrylcholinesterase sensitivity to physostigmine and neostigmine.
Spiro Heterocyclic Compounds as Potential Anti-Alzheimer agents (Part 2): their Metal Chelation Capacity, POM Analyses and DFT Studies.
Spotlight on cerebrolysin in dementia.
Spotlight on rivastigmine transdermal patch†: in dementia of the Alzheimer's type.
Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.
Stereoselective glucuronidation metabolism, pharmacokinetics, anti-amnesic pharmacodynamics, and toxic properties of vasicine enantiomers in vitro and in vivo.
Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients.
Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism.
Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.
Structure-activity relationship studies of benzyl-, phenethyl-, and pyridyl-substituted tetrahydroacridin-9-amines as multitargeting agents to treat Alzheimer's disease.
Structure-activity relationship, in vitro and in vivo evaluation of novel dienyl sulphonyl fluorides as selective BuChE inhibitors for the treatment of Alzheimer's disease.
Structure-based virtual screening leading to discovery of highly selective butyrylcholinesterase inhibitors with solanaceous alkaloid scaffolds.
Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer's disease: a cumulative meta-analysis and trial sequential analysis.
Subchronic use of rivastigmine increases procognitive flexibility across multimodal behavioral tasks in healthy male rats.
Suboptimal Baseline Serum Vitamin B12 Is Associated With Cognitive Decline in People With Alzheimer's Disease Undergoing Cholinesterase Inhibitor Treatment.
Suicide in two patients with a diagnosis of probable Alzheimer disease.
Switching cholinesterase inhibitors in older adults with dementia.
Switching cholinesterase inhibitors in patients with Alzheimer's disease.
Symptomatic treatments in Alzheimer's disease in 2016: a study from Memory centers in France.
Syncope with cholinesterase inhibitors.
Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease.
Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease.
Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease.
Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives.
Synthesis and bio-evaluation of a novel selective butyrylcholinesterase inhibitor discovered through structure-based virtual screening.
Synthesis and bioevaluation of new tacrine-cinnamic acid hybrids as cholinesterase inhibitors against Alzheimer's disease.
Synthesis and Biological Assessment of Racemic Benzochromenopyrimidinimines as Antioxidant, Cholinesterase, and A?1-42 Aggregation Inhibitors for Alzheimer's Disease Therapy.
Synthesis and biological evaluation of 3-arylbenzofuranone derivatives as potential anti-Alzheimer's disease agents.
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
Synthesis and Biological Evaluation of Benzochromenopyrimidinones as Cholinesterase Inhibitors and Potent Antioxidant, Non-Hepatotoxic Agents for Alzheimer's Disease.
Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease.
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease.
Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
Synthesis and in vitro evaluation of 7-methoxy-N-(pent-4-enyl)-1,2,3,4-tetrahydroacridin-9-amine-new tacrine derivate with cholinergic properties.
Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment.
Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease.
Synthesis and In Vitro Screening of Novel Heterocyclic ?-d-Gluco- and ?-d-Galactoconjugates as Butyrylcholinesterase Inhibitors.
Synthesis and Initial Characterization of a Selective, Pseudo-irreversible Inhibitor of Human Butyrylcholinesterase as PET Tracer.
Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease.
Synthesis and Preliminary Evaluation of Phenyl 4-123I-Iodophenylcarbamate for Visualization of Cholinesterases Associated with Alzheimer Disease Pathology.
Synthesis and Preliminary Evaluation of Piperidinyl and Pyrrolidinyl Iodobenzoates as Imaging Agents for Butyrylcholinesterase.
Synthesis and structure-activity relationship study of tacrine-based pyrano[2,3-c]pyrazoles targeting AChE/BuChE and 15-LOX.
Synthesis of 5-methyl-2,4-dihydro-3H-1,2,4-triazole-3-one's aryl Schiff base derivatives and investigation of carbonic anhydrase and cholinesterase (AChE, BuChE) inhibitory properties.
Synthesis of 9-Aminoacridine Derivatives as Anti-Alzheimer Agents.
Synthesis of carbon-11-labeled bivalent ?-carbolines as new PET agents for imaging of cholinesterase in Alzheimer's disease.
Synthesis of donepezil-based multifunctional agents for the treatment of Alzheimer's disease.
Synthesis of N-phenylsulfonamide derivatives and investigation of some esterase enzymes inhibiting properties.
Synthesis of novel bis-sulfone derivatives and their inhibition properties on some metabolic enzymes including carbonic anhydrase, acetylcholinesterase, and butyrylcholinesterase.
Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
Synthesis of novel purine nucleosides towards a selective inhibition of human butyrylcholinesterase.
Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics.
Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease.
Synthesis, Characterization, and Inhibition Study of Novel Substituted Phenylureido Sulfaguanidine Derivatives as ?-Glycosidase and Cholinesterase Inhibitors.
Synthesis, cytotoxicity and molecular modelling studies of new phenylcinnamide derivatives as potent inhibitors of cholinesterases.
Synthesis, molecular docking, acetylcholinesterase and butyrylcholinesterase inhibitory potential of thiazole analogs as new inhibitors for Alzheimer disease.
Synthesis, molecular docking, and biological activity of 2-vinyl chromones: Toward selective butyrylcholinesterase inhibitors for potential Alzheimer's disease therapeutics.
Synthesis, molecular modeling and evaluation of novel N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone derivatives as dual inhibitors for cholinesterases and A? aggregation.
Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimer's disease.
Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias.
Systematic Review of Cholinesterase Inhibitors on Cognition and Behavioral Symptoms in Patients of Chinese Descent with Alzheimer's Disease, Vascular Dementia, or Mixed Dementia.
Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia.
Tackling dementia in patients with Parkinson's disease.
Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells.
Tacrine hydrochloride treatment IND: methods for rapid physician and patient enrollment and data retrieval.
Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography.
Tacrine sinusoidal uptake and biliary excretion in sandwich-cultured primary rat hepatocytes.
Tacrine therapy for the dementia of Alzheimer's disease.
Tacrine, an Oral Acetylcholinesterase Inhibitor, Induced Hepatic Oxidative Damage, Which Was Blocked by Liquiritigenin through GSK3-beta Inhibition.
Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors.
Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease.
Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment.
Targeting Alzheimer's disease by investigating previously unexplored chemical space surrounding the cholinesterase inhibitor donepezil.
Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease.
Ten years of cholinesterase inhibitors.
Terpenes and Phenylpropanoids as Acetyl- and Butyrylcholinesterase Inhibitors: A Comparative Study.
Tetrahydroaminoacridine block of N-methyl-D-aspartate-activated cation channels in cultured hippocampal neurons.
Tetrahydroaminoacridine improves the recency effect in Alzheimer's disease.
THA disrupts mismatch negativity in Alzheimer disease.
THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease.
The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial.
The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression.
The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: Interim Results after Two Years of Treatment.
The ASCOMALVA trial: Association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: Interim results.
The Association Between the Use of Cholinesterase Inhibitors and Cardiovascular Events Among Older Patients With Alzheimer Disease.
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
The benefits of cholinesterase inhibitors: managing the behavioral and neuropsychiatric symptoms of Alzheimer's disease.
The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations.
The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease.
The butyrylcholinesterase K variant confers structurally-derived risks for Alzheimer's pathology.
The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer's disease in women.
The butyrylcholinesterase K-variant shows similar cellular protein turnover and quaternary interaction to the wild-type enzyme.
The butyrylcholinesterase knockout mouse a research tool in the study of drug sensitivity, bio-distribution, obesity and Alzheimer's disease.
The cerebrovascular effects of physostigmine are not mediated through the substantia innominata.
The cerebrovascular role of the cholinergic neural system in Alzheimer's disease.
The cholinergic deficiency syndrome and its therapeutic implications.
The cholinergic hypothesis of Alzheimer's disease: a review of progress.
The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.
The cholinesterase inhibitors.
The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study.
The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
The cognitive effects of cholinesterase inhibitor treatment in every-day practice.
The coming problem of HIV-associated Alzheimer's disease.
The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?
The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach.
The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.
The effect of APOE ?4 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging.
The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort.
The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.
The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques.
The effect of food and time of administration on the pharmacokinetic and pharmacodynamic profile of metrifonate.
The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials.
The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex.
The effects of donepezil on quantitative EEG in patients with Alzheimer's disease.
The effects of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease.
The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory.
The efficacy and safety of memantine for the treatment of Alzheimer's disease.
The evidence for the efficacy of cholinesterase inhibitors in the treatment of Alzheimer's disease is convincing.
The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
The exploration of thienothiazines as selective butyrylcholinesterase inhibitors.
The Impact of a Long-Term Rivastigmine and Donepezil Treatment on All-Cause Mortality in Patients With Alzheimer's Disease.
The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Régie de l'Assurance Maladie du Québec database.
The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people.
The impact of some phenolic compounds on serum acetylcholinesterase: kinetic analysis of an enzyme/inhibitor interaction and molecular docking study.
The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase.
The International Psychogeriatric Association--ninth congress. 15-20 August 1999, Vancouver, Canada.
The interplay of neurotransmitters in Alzheimer's disease.
The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
The modulatory role of prime identified compounds in Geophila repens in mitigating scopolamine-induced neurotoxicity in experimental rats of Alzheimer's disease via attenuation of cholinesterase, ?-secretase, MAPt levels and inhibition of oxidative stress imparts inflammation.
The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer's disease.
The neuroprotective mechanism of action of the multimodal drug ladostigil.
The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.
The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
The next generation of cholinesterase inhibitors.
The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.
The oxidation products of melatonin derivatives exhibit acetylcholinesterase and butyrylcholinesterase inhibitory activity.
The pharmacist's role in managing patients with Alzheimer's disease.
The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.
The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease.
The practical management of cognitive impairment and psychosis in the older Parkinson's disease patient.
The ratio of acetylcholinesterase to butyrylcholinesterase influences the specificity of assays for each enzyme in human brain.
The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate.
The response of the autonomic nervous system to the cholinesterase inhibitor, donepezil.
The Role of Butyrylcholinesterase and Iron in the Regulation of Cholinergic Network and Cognitive Dysfunction in Alzheimer's Disease Pathogenesis.
The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease.
The safety and tolerability of donepezil in patients with Alzheimer's disease.
The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
The second Leicester survey of memory clinics in the British Isles.
The Serum Protein and Lipid Oxidation Marker Levels in Alzheimer's Disease and Effects of Cholinesterase Inhibitors and Antipsychotic Drugs Therapy.
The significance of the activity of CSF cholinesterases in dementias.
The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease.
The use of atypical antipsychotics in nursing homes.
The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.
The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease.
The use of herbal medicine in Alzheimer's disease-a systematic review.
The utility of muscarinic agonists in the treatment of Alzheimer's disease.
Thioesters for the in vitro evaluation of agents to image brain cholinesterases.
Thyroid function in patients with Alzheimer's disease treated with cholinesterase inhibitors.
To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease.
Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors.
Traditional Chinese medicines and Alzheimer's disease.
Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors.
Treating Alzheimer's disease with cholinesterase inhibitors: what have we learned so far?
Treating Alzheimer's disease: do clinical trial methods produce unnecessary practitioner dilemmas?
Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.
Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study.
Treatment effects of EGb 761 and cholinesterase inhibitors--why available studies do not demonstrate superiority of the latter.
Treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in Alzheimer's disease: a longitudinal functional MRI study.
Treatment of advanced Alzheimer's disease with cholinesterase inhibitors.
Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.
Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants.
Treatment of Alzheimer's disease with cholinesterase inhibitors.
Treatment of Alzheimer's disease. New developments.
Treatment of attention deficits in neurological disorders.
Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors.
Treatment of Mild Cognitive Impairment.
Treatment of psychosis and dementia in Parkinson's disease.
Treatment of typical Charles Bonnet syndrome with donepezil.
Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Treatment strategies in Alzheimer's disease with a focus on early pharmacological interventions.
Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.
Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study.
Trends and disparities in the use of cholinesterase inhibitors to treat Alzheimer's disease dispensed by the Brazilian public health system - 2008 to 2014: a nation-wide analysis.
Tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one scaffold derivatives: Synthesis and biological evaluation as selective BuChE inhibitors.
Trospium and cognition in patients with late onset Alzheimer disease.
Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease.
TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.
Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.
Ultrastructural localization of butyrylcholinesterase in senile plaques in the brains of aged and Alzheimer disease patients.
Ultrastructural localization of butyrylcholinesterase on neurofibrillary degeneration sites in the brains of aged and Alzheimer's disease patients.
Update on rivastigmine.
Use of antidementia agents in vascular dementia: beyond Alzheimer disease.
Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
Use of artificial networks in clinical trials: a pilot study to predict responsiveness to donepezil in Alzheimer's disease.
Use of cholinesterase inhibitors for treatment of Alzheimer disease.
Use of cholinesterase inhibitors in Alzheimer's disease.
Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.
Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias.
Use of Cholinesterase Inhibitors Increases Initiation of Urinary Anticholinergics in Persons with Alzheimer's Disease.
Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands.
Using a distribution-based approach and systematic review methods to derive minimum clinically important differences.
Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups.
Utility of an effect size analysis for communicating treatment effectiveness: a case study of cholinesterase inhibitors for Alzheimer's disease.
Utilization of Antihypertensives, Antidepressants, Antipsychotics, and Hormones in Alzheimer Disease.
Utilizing combination therapy in the treatment of Alzheimer's disease.
Velnacrine for Alzheimer's disease.
Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
What are the benefits of cognitive enhancers for Alzheimer's Disease: use of Population Impact Measures.
What are the treatment options for patients with severe Alzheimer's disease?
What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors?
Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?
Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain.
Withanolides, a new class of natural cholinesterase inhibitors with calcium antagonistic properties.
Withanolides: Biologically Active Constituents in the Treatment of Alzheimer Disease.
[A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia]
[Access to medicines for Alzheimer's disease provided by the Brazilian Unified National Health System in Minas Gerais State, Brazil].
[Advances in the therapy of dementia.]
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko]
[Alzheimer's disease and cholinesterase]
[Anticholinesterases; peripheral and central effects].
[Antidementia drugs - response or non-response?]
[Autosomal dominant Alzheimer's disease. Study of a Moroccan family]
[Biological therapies of behavioral and psychological symptoms of dementia: update and prospects]
[Cardiovascular effects of cholinesterase inhibitors in Alzheimer's disease]
[Changes in butyrylcholinesterase activity in patients with Alzheimer disease treated with acetylcholinesterase inhibitors.]
[Changing the anticholinesterase in Alzheimer's disease]
[Cholinergic deficiency syndrome as an indicator for the cholinesterase inhibitors]
[Cholinesterase activity assays and their use in the diagnosis of various pathological states including poisoning by neurotoxic agents].
[Cholinesterase inhibitor therapy in long term care settings]
[Cholinesterase inhibitors and Alzheimer's disease: meta-analysis of the verification of effectiveness, origin and bias of results in published studies]
[Cholinesterase inhibitors and depression in the elderly]
[Cholinesterase inhibitors for Alzheimer disease: preliminary recommendations for treatment. Dutch Society for Psychiatry, Section of Geriatric Psychiatry]
[Cholinesterase inhibitors in Alzheimer disease: preliminary recommendations for the practice]
[Cholinesterase inhibitors in Alzheimer disease: preliminary recommendations for treatment]
[Cholinesterase inhibitors in Alzheimer disease; preliminary recommendations for the practice]
[Cholinesterase inhibitors in Alzheimer's disease]
[Cholinesterase inhibitors in dementia: the precarious balance between efficacy and safety]
[Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?]
[Cholinesterase inhibitors in the treatment of mixed dementia].
[Dementia and Alzheimer disease. Early detection and treatment]
[Dementia-current knowledge and significance for ENT specialists]
[Detection of Alzheimer's disease in general medicine: preliminary results of a Sentinelles general practitioner's network survey]
[Donepezil in patients with Alzheimer's disease--a critical appraisal of the AD2000 study]
[Drug therapy for Alzheimer's disease]
[Gerontology]
[Inhibitory effects of sinapine on activity of acetylcholinesterase in cerebral homogenate and blood serum of rats]
[Interaction of donepezil and muscular blockers in Alzheimer's disease]
[Medical treatment of Alzheimer's disease]
[Mortality rates in patients with Alzheimer's disease treated with atypical neuroleptic drugs]
[Mortality-associated factors in patients with Alzheimer's disease treated with galantamine]
[Neuropsychological assessment in the diagnosis and differential diagnosis of fronto-temporal dementia.]
[New therapeutic options in Alzheimer's disease]
[Newly approved drugs for Alzheimer disease: effectiveness and limitation].
[Nicotinic acetylcholine receptor in Alzheimer's disease].
[Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands]
[Perspective of dementia therapy]
[Posterior cortical atrophy. Pathology, diagnosis and treatment of a rare form of dementia].
[Prescription of cholinesterase inhibitors in Alzheimer's disease in France in 2000-2001: an assessment of compliance with national guidelines for diagnosis and follow-up]
[Present trends in the development of drugs within the cholinesterase inhibitor group as therapeutic agents for Alzheimer's disease]
[Problems and questions of pharmacological therapy of Alzheimer's disease with cholinesterase inhibitors]
[Quality of life and dementia. I. Model of assessment of wellbeing in dementia patients]
[Relation between Pisa syndrome and choline esterase inhibitors in a cohort of Alzheimer's disease patients]
[Rivastigmine in a case of autopsy proved frontotemporal dementia (Pick's disease)]
[Severe bradycardia in general anaesthesia in a patient treated with cholinesterase inhibitors for dementia.]
[Study on the activity of cholinesterase and its distribution in molecular form in the cerebrospinal fluid of patients with Alzheimer's disease, a possible diagnostic marker?]
[Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine]
[The clinical relevance of memantine use]
[The effect of a cholinesterase inhibitor on the vitality in Alzheimer disease]
[The efficacy of donepezil in Alzheimer's disease]
[Treatment for non-cognitive symptoms in Alzheimer's disease]
[Treatment of Alzheimer's disease according to the S3 guidelines on dementia. Choline esterase inhibitors for all and for ever?].
[Treatment of Alzheimer's disease utilising the best available evidence-based medicine -- utopia?]
[Treatment of dementia with Lewy bodies]
[Treatment of dementia].
[Treatment pattern of Alzheimer's disease with cholinesterase inhibitors (TRAIN study)]
[Updated Dementia guideline: reflections from primary care].
[Use of cholinesterase inhibitors in Alzheimer disease]
Amblyopia
Donepezil Does Not Enhance Perceptual Learning in Adults with Amblyopia: A Pilot Study.
Amebiasis
THE SERUM CHOLINESTERASE LEVELS IN AMOEBIASIS.
Amnesia
Ameliorative effect of deoxyvasicine on scopolamine-induced cognitive dysfunction by restoration of cholinergic function in mice.
Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction.
An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors.
Characterization of the effects of scopolamine on the habituation of exploratory activity: differential effects of oxotremorine and physostigmine.
Comparison of three different extracts of Centella asiatica for anti-amnesic, antioxidant and anticholinergic activities: in vitro and in vivo study.
Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice.
Donepezil abolishes anticholinergic activity in a patient with amnesia.
Effects of a new synthetic butyrylcholinesterase inhibitor, HBU-39, on cell proliferation and neuroblast differentiation in the hippocampal dentate gyrus in a scopolamine-induced amnesia animal model.
Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.
Efficacy study of Prunus amygdalus (almond) nuts in scopolamine-induced amnesia in rats.
FK960, a potential anti-dementia drug, increases synaptic density in the hippocampal CA3 region of aged rats.
Long-lasting antiamnesic effect of a novel anticholinesterase inhibitor (MF268).
Role of cholinergic and GABAergic neuronal systems in cycloheximide-induced amnesia in mice.
Synthesis and evaluation of novel 4-[(3H,3aH,6aH)-3-phenyl)-4,6-dioxo-2-phenyldihydro-2H-pyrrolo[3,4-d]isoxazol-5(3H,6H,6aH)-yl]benzoic acid derivatives as potent acetylcholinesterase inhibitors and anti-amnestic agents.
Amyloidosis
Serum esterase activity in reactive systemic amyloidosis and its relation to amyloid A degrading activity.
Amyotrophic Lateral Sclerosis
Acetylcholinesterase and ATPases in motor neuron degenerative diseases.
Cholinesterase activity of whole blood and plasma in amyotrophic lateral sclerosis.
Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A controlled study of physostigmine versus neostigmine.
Anaphylaxis
PLASMA PHOSPHATASE, CHOLINESTERASE AND PEPTONASE IN ANAPHYLACTIC SHOCK.
[Iodine 131 with autography, hyperglycemia, cholinesterase, metabolism, thiomidil, anaphylactic shock, immunisation in hibernation.]
[On changes of cholinesterase activity in the blood of the rabbit by sensitization and anaphylactic shock.]
[Radioactive iodine with autography, hyperglycemia, cholinesterase, metabolism, thiomidil, anaphylactic shock, and immunization in hibernation.]
[Role of cholinesterase in the mechanism of certain phenomena of anaphylactic shock.]
[Variations of the cholinesterase power of the serum during anaphylactic shock and asthmatic attack artificially induced by acetylcholine and histamine aerosols.]
Anemia
A patient with Churg-Strauss syndrome who underwent endoscopic sinus surgery under general anesthesia -A case report-.
Analysis of functional abnormalities uncovered during preoperative evaluation of donor candidates for living-related liver transplantation.
Anemia: an indicator for malnutrition in the elderly.
ERYTHROCYTE CHOLINESTERASE ACTIVITY IN HEMOLYTIC ANEMIAS.
Erythrocyte cholinesterase activity in normal pregnancy and in megaloblastic and other anemias of pregnancy and the puerperium.
Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion.
Plasma fibrinogen, cholinesterase activity, and anemia: utility of fibrinogen in multiphasic screening and in assessing the activity of diseases.
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2?years of age - a multicenter retrospective study.
The cholinesterase of erythrocytes in anemias.
[Erythrocyte cholinesterase in neoplastic anemia]
[Factors for the onset of and the exacerbation of tuberculosis. 4. Clinical factors related to the onset and exacerbation of tuberculosis. b. Middle-aged and elderly patients]
[Research in the relation between the defense action of certain antianemic substances (vitamin B12, pteroylglutamic acid) and the cholinesterase effect of the serum in experimental anemia of the rat].
Anemia, Aplastic
GM-CSF-mediated impairment of liver to synthesize albumin, cholinesterase, and cholesterol.
Anemia, Hypochromic
[Endoscopic diagnosis of colonic tuberculosis]
Anemia, Pernicious
A study of cholinesterase activity of the blood of patients with pernicious anemia.
CHOLINE ESTERASE OF BLOOD CELLS AND PLASMA IN BLOOD DYSCRASIAS, WITH SPECIAL REFERENCE TO PERNICIOUS ANEMIA.
[Cholinesterase in the plasma, erythrocytes and whole blood in pernicious anemia and leukemia.]
Anencephaly
Ratio of immunochemically determined amniotic fluid acetylcholinesterase to butyrylcholinesterase in the differential diagnosis of fetal abnormalities.
Aneurysm
Activity of enzymes with different subcellular localization in the blood plasma of patients with aortic aneurysm.
Cholinergic treatment of amnesia following basal forebrain lesion due to aneurysm rupture--an open-label pilot study.
Angina Pectoris
[The effect of new cholinesterase retarding substance on sympathicotonic circulation disorder, with special reference to angina pectoris.]
Angioedema
Severe angioedema causing airway obstruction after anterior cervical surgery.
Anhedonia
Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats.
Anisocoria
[The clinical features of myasthenia gravis affecting nonskeleton muscles]
Anterior Wall Myocardial Infarction
[Electrocardiographic changes in acute organophosphate poisoning]
Aphasia, Primary Progressive
Primary Progressive Aphasia as a Prodromal State of Dementia With Lewy Bodies: A Case Report.
Apnea
A Case of Pseudocholinesterase Deficiency Resulting From Malnutrition.
A color reaction based rapid screening for null activity of butyrylcholinesterase: a step towards point of care screening for succinylcholine apnea.
A mutation linked with autism reveals a common mechanism of endoplasmic reticulum retention for the alpha,beta-hydrolase fold protein family.
A single mutation near the C-terminus in alpha/beta hydrolase fold protein family causes a defect in protein processing.
Analysis of mutations in the plasma cholinesterase gene of patients with a history of prolonged neuromuscular block during anesthesia.
Apnea and atypical pseudocholinesterase.
APNEA DUE TO INHERITANCE OF ATYPICAL PSEUDOCHOLINESTERASE.
Apnea following succinylcholine associated with atypical cholinesterase.
Apnea in an atypical-fluoride resistant (E1aE1f) heterozygote for serum cholinesterase.
Atypical Cholinesterase and Prolonged Apnea During Electroconvulsive Therapy.
Atypical plasma cholinesterase, succinylcholine, and prolonged apnea.
Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in an Australian population.
Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.
Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.
Characterization of a novel butyrylcholinesterase point mutation (p.Ala34Val), "silent" with mivacurium.
Characterization of four BCHE mutations associated with prolonged effect of suxamethonium.
Cholinesterase unit establishment and issuing of >>Warning Cards<< for carriers of suxamethonium sensitive serum butyrylcholinesterase variants.
Delayed recovery from paralysis associated with plasma cholinesterase deficiency.
Determination of butyrylcholinesterase (BChE) phenotypes to predict the risk of prolonged apnea in persons receiving succinylcholine in the healthy population of western Iran.
Distribution of cholinesterase activity in the population of Trinidad.
Ethnic differences in the frequency of distribution of serum cholinesterase activity in the Iranian population.
Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine.
Hereditary cholinesterase deficiency: a report of a family with two rare genotypes.
Heterozygous Atypical Cholinesterase: Management During ECT.
Increased sensitivity to succinylcholine in a patient heterozygous for the silent and the fluoride-resistant gene.
Is succinyldicholine the substrate of choice for the measurement of cholinesterase activity?
Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India.
Novel mutations in the BCHE gene in patients with no butyrylcholinesterase activity.
Pesticide poisoning, succinylcholine-induced apnea, and pseudocholinesterase.
Plasma cholinesterase and the duration of succinylcholine-induced apnea.
Prolonged apnea after ECT in organophosphorus poisoning - the need to redefine norms.
Prolonged apnea after orthognathic surgery due to atypical cholinesterase.
Prolonged apnea caused by inherited cholinesterase deficiency after strabismus surgery.
Prolonged apnea following modified electroconvulsive therapy with suxamethonium.
Prolonged apnea following succinylcholine administration in undiagnosed acute organophosphate poisoning.
Prolonged neuromuscular blockade as a result of malnutrition-induced pseudocholinesterase deficiency.
Prolonged Neuromuscular Paralysis Following Rapid-Sequence Intubation with Succinylcholine (April).
Prolonged postoperative apnea complicating gynecologic surgery; atypical cholinesterase and myasthenia gravis.
Prolonged postoperative apnea with pseudocholinesterase deficiency.
Prolonged postoperative succinylcholine-induced apnea with pseudocholinesterase deficiency.
Prolonged succinylcholine-induced apnea caused by atypical cholinesterase: report of case.
Prolonged succinylcholine-induced paralysis in organophosphate insecticide poisoning.
Pseudocholinesterase abnormalities as a cause of postanesthetic apnea.
Rapid detection of BCHE atypical variant (p.Asp70Gly) by high resolution melting curve analysis.
Reversal of succinylcholine induced apnea with an organophosphate scavenging recombinant butyrylcholinesterase.
Succinylcholine-induced prolonged apnea in a 3-week-old newborn: treatment with human plasma cholinesterase.
Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.
The allele frequency of T920C mutation in butyrylcholinesterase gene is high in an Indian population.
The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26.
The relation between plasma cholinesterase and prolonged apnea caused by succinylcholine.
Therapy of prolonged apnea after suxamthonium with purified pseudocholinesterase. New data on kinetics of the hydrolysis of succinyldicholine and succinylmonocholine and further data on N-acetyltransferase-polymorphism.
Transient respiratory depression of the newborn. Its occurrence after succinylcholine administration to the mother.
Two new mutations of the human BCHE gene (IVS3-14T>C and L574fsX576).
[4 families with silent cholinesterase variant]
[A rare case of silent cholinesterase genetic variant (author's transl)]
[Administration of cholinesterase in apnea induced by suxamethonium]
[Apnea caused by succinylcholine and its relation to serum cholinesterase.]
[Cholinesterase and prolonged apnea due to succinylcholine]
[Data on serum cholinesterase activity in cases of prolonged apnea due to succinylcholine]
[EFFECT OF THE STORAGE ON THE PSEUDOCHOLINESTERASE ACTIVITY IN DONOR'S BLOOD AND ITS SIGNIFICANCE IN THE TREATMENT OF APNEA.]
[Emergency from anesthesia in small children. From laryngospasm to prolonged apnea]
[Gene analysis of human cholinesterase variants]
[Phenotype of plasma cholinesterase in prolonged apnea and sensitivity to succinylcholine]
[Plasma cholinesterase (CHE, pseudocholinesterase), its importance in liver diseases and prolonged succinyldicholine-induced apnea]
[Plasma cholinesterase variations as a result of prolonged neuromuscular blockade. Review and problems encountered in two cases of prolonged neuromuscular blockade after muscle relaxation with succinylcholine as compared to mivacurium]
[Polymorphism of plasma cholinesterase in Pyrennees populations. Problems in geographic hematology and pharmacogenetics]
[Procedure for identifying atypical variants of pseudocholinesterase for the prevention of prolonged apnea induced by succinylcholine]
[Prolonged apnea after suxamethonium related to congenital abnormality of plasma pseudocholinesterase]
[Prolonged apnea and cholinesterase defficiency]
[Prolonged apnea caused by atypical pseudocholinesterase]
[Prolonged apnea caused by succinylcholine iodide, related to a lowered blood cholinesterase content.]
[Prolonged apnea due to atypical pseudocholinesterase]
[Pseudocholinesterase deficiency; a complication in bronchoscopy in anesthesia and apnea.]
[Relation between serum cholinesterase polymorphism, long-term apnea and hypoventilation during surgery and in the postoperative period]
[Research on serum cholinesterase activity in subjects with prolonged apnea caused by succinylcholine]
[Serum butyrylcholinesterase variants in eastern Santiago population]
[Succinylcholine apnea in a patient homozygotic for atypical cholinesterase gene]
[Succinylcholine-induced apnea and familial cholinesterase deficiency]
[Succinyldicholin sensitivity resulting from genetically determined serumcholinesterase variants]
[The effect of etomidate on the activity of human pseudocholinesterase. In vivo-in vitro-enzymekinetics (author's transl)]
Appendicitis
[Cholinesterase activity in acute appendicitis]
Arrhythmia, Sinus
Monitoring the chronic effects of anticholinesterase pesticides in aerial applicators.
Arrhythmias, Cardiac
Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure.
Inhibitory effect of quinidine on plasma pseudocholinesterase activity in pregnant women.
Manifestations of and risk factors for acute myocardial injury after acute organophosphorus pesticide poisoning.
Pseudocholinesterase in patients with coronary artery disease with cardiac arrhythmias.
Role of plasma pseudocholinesterase activity in the diagnosis of acute myocardial infarction with special reference to cardiac arrhythmias.
[Complete atrioventricular block during galantamine therapy]
Arteritis
[Studies on blood cholesterase in chronic arteritis; activities of certain cholinesterase inhibitors in normal subjects and in chronic arteritis.]
Arthritis, Rheumatoid
Association between butyrylcholinesterase activity and phenotypes, paraoxonase192 rs662 gene polymorphism and their enzymatic activity with severity of rheumatoid arthritis: correlation with systemic inflammatory markers and oxidative stress, preliminary report.
Choline esterase activity in rheumatoid arthritis.
Cholinesterase activity in patients with rheumatoid arthritis.
Arthrogryposis
Determination of cholinesterase and acetylcholinesterase in amniotic fluid. Uses in prenatal diagnosis and quality control.
Arthus Reaction
[CHOLINESTERASE IN SERUM AND ERYTHROCYTES DURING THE ARTHUS PHENOMENON.]
Ascariasis
[Cholinesterase activity and acetylcholine of the blood serum in experimental ascariasis.]
[The effect of thiamine on cholinesterase activity and the quantity of acetylcholine in the blood serum in experimental ascariasis.]
Asphyxia Neonatorum
[CHOLINESTERASE ACTIVITY OF THE BLOOD SERUM IN FETAL DEATH, ASPHYXIA NEONATORUM AND FETAL DEFORMITIES.]
Asthma
Acetylcholine and cholinesterase in the blood of patients suffering with bronchial asthma.
Microbial biotransformation of bioactive and clinically useful steroids and some salient features of steroids and biotransformation.
Pharmacologic treatments of dementia.
Plasma esterase activity in patients with aspirin-sensitive asthma or urticaria.
Risk factors for allergy due to the two-spotted spider mite (Tetranychus urticae) among table grape farm workers.
[Blood levels of acetylcholine and serum cholinesterase activity in children with neurodermatitis constitutionalis with and without bronchial asthma]
[Cholinesterase in the blood serum in allergic bronchial asthma.]
[Disorders of cholinergic regulation in patients with bronchial asthma]
[Erythrocyte acetylcholinesterase activity and non-specific cholinesterase and ceruloplasmin activity in serum of patients with bronchial asthma]
Astrocytoma
Identification of hybrid cholinesterase forms consisting of acetyl- and butyrylcholinesterase subunits in human glioma.
Asymptomatic Infections
Cholinesterase as an inflammatory marker of subclinical infection of dairy cows infected by Neospora caninum and risk factors for disease.
Ataxia
Clinical signs and biochemical changes in calves caused by injection of ivermectin.
Relationship between the pharmacological effects and the biodisposition of [3H]diisopropylfluorophosphate in mice after inhalation.
Striatal neurochemical changes and motor dysfunction in mipafox-treated animals.
Atherosclerosis
Pseudocholinesterase and lipoprotein lipase in atherosclerosis.
Rhizoma Coptidis for Alzheimer's Disease and Vascular Dementia: A Literature Review.
[Changes of choline, cholesterol and cholinesterase in the blood in atherosclerosis.]
[Dynamic activity of cholinesterase and choline content in various forms of atherosclerosis.]
[Effect of vitamin E on activity of blood cholinesterase in atherosclerosis.]
[On cholinesterase activity in rabbit brain during experimental atherosclerosis and functional loading]
Atrial Fibrillation
Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support.
Changes of myocardial enzyme activities in atrial fibrillation.
Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease.
The production of block and auricular fibrillation in the heart-lung preparation by inhibitors of cholinesterase.
[Changes in blood cholinesterase activity in patients with heart defects accompanied by auricular fibrillation treated by electric defibrillation]
Avitaminosis
[Role of hormonal and seasonal factors in the effect of vitamin E on cholinesterase activity in the nervous system]
Babesiosis
Evaluation of some acute phase proteins in cattle naturally infected with Babesia bigemina.
The effect of diminazene aceturate on cholinesterase activity in dogs with canine babesiosis.
Bacteremia
Liver function tests in patients with bacteremia.
Bacterial Infections
Liver function tests in patients with bacteremia.
Value of Serum Cholinesterase Activity in the Diagnosis of Septic Shock Due to Bacterial Infections.
[Decrease in plasmatic cholinesterase activity in severe bacterial infections: comparison with the decrease observed in severe liver cirrhosis]
[Research on risk factors of short-term outcome in AIDS patients with pneumocystis pneumonia].
Basal Ganglia Diseases
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
Beriberi
[True and pseudo cholinesterase in the central nervous system and blood of pigeons with beriberi]
beta-Thalassemia
Biochemical genetics and mental retardation: a study of hemoglobins, Australia antigen and the enzymes pseudocholinesterase and glucose-6-phosphate dehydrogenase.
[SERUM CHOLINESTERASE IN PATIENTS WITH COOLEY'S ANEMIA AND IN THEIR FAMILIES.]
Biliary Tract Diseases
Colorimetric determination of serum cholinesterase: its value in hepatic and biliary tract diseases.
[Ceruloplasmin, cholinesterase and aldolase activity in children with biliary tract disease]
Bradycardia
Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.
Bradycardia produced by pyridostigmine and physostigmine.
Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.
Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.
Causes of syncope in patients with Alzheimer's disease treated with donepezil.
Cholinergic Crisis Owing to Distigmine Bromide Complicated by Hyperosmolar Hyperglycemic State.
Cholinesterase inhibitor treatment may double the risk of hospitalisation for bradycardia.
Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study.
Cholinesterase Inhibitors and Incidence of Bradycardia in Patients with Dementia in the Veterans Affairs New England Healthcare System.
Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists.
Different properties of the bradycardia produced by neostigmine and edrophonium in the cat.
Donepezil overdose: a tenfold dosing error.
Electrocardiogram Changes of Donepezil Administration in Elderly Patients with Ischemic Heart Disease.
Fresh frozen plasma as a successful antidotal supplement in acute organophosphate poisoning.
Intra-operative bradycardia in a patient with Alzheimer's disease treated with two cholinesterase inhibitors.
Modulatory effect of brain acetylcholine on reflex-induced bradycardia and tachycardia in conscious rats.
Much caution does no harm! Organophosphate poisoning often causes pancreatitis.
Pharmacologic treatments of dementia.
Prevalence of positive carotid sinus massage and related risk of syncope in patients with Alzheimer's disease.
Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.
Syncope with cholinesterase inhibitors.
The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada.
[Acute respiratory failure associated with cholinergic crisis: report of five cases and review of the literature].
[Analysis of the bradycardia action of cholinesterase inhibitor paraoxon (diethyl-p-nitrophenylphosphate) on isolated hearts of warm-blooded animals.]
[Hemodynamic effects in antagonism of neuromuscular blockage: atropine-pyridostigmine versus ipratropium bromide-pyridostigmine]
[Reversal of neuromuscular block with sugammadex in five heart transplant pediatric recipients].
[Severe bradycardia in general anaesthesia in a patient treated with cholinesterase inhibitors for dementia.]
[Sugammadex, a new drug for reversion of muscle relaxants].
Brain Concussion
Evaluating the Memory Enhancing Effects of Angelica gigas in Mouse Models of Mild Cognitive Impairments.
Brain Diseases
Clinical diagnostic significance of prealbumin, cholinesterase and retinol binding protein in liver cirrhosis combined with encephalopathy.
Delayed-onset encephalopathy and coma in acute organophosphate poisoning in humans.
Etiology and prognosis of liver cirrhosis in elderly patients.
Poor prediction of blood transfusion requirements in adult liver transplantations from preoperative variables.
Predictive value of serum procollagen-III-peptide for the survival of patients with cirrhosis.
Predictors of one-year pretransplant survival in patients with cirrhosis.
Role of Nicotinic and Muscarinic Receptors on Synaptic Plasticity and Neurological Diseases.
Survival and prognostic indicators in compensated and decompensated cirrhosis.
The utility of EEG in dementia: a clinical perspective.
Tissue Distribution and Pharmacodynamics of Rivastigmine after Intranasal and Intravenous Administration in Rats.
[Endogenous digitalis-like factor in liver cirrhosis and cholestasis]
Brain Edema
Cerebral edema induced in mice by a convulsive dose of soman. Evaluation through diffusion-weighted magnetic resonance imaging and histology.
Changes in mouse brain metabolism following a convulsive dose of soman: a proton HRMAS NMR study.
Brain Infarction
Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment.
Increased monoamine metabolite concentrations and cholinesterase activities in cerebrospinal fluid of patients with acute stroke.
Brain Injuries
Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury.
Effect of tetrahydroaminoacridine, a cholinesterase inhibitor, on cognitive performance following experimental brain injury.
Nasal midazolam as a novel anticonvulsive treatment against organophosphate-induced seizure activity in the guinea pig.
Unexpected extrapyramidal symptoms and pulmonary aspergillosis in exertional heatstroke with fulminant liver failure: a case report.
Brain Injuries, Traumatic
Cholinomimetic agents and neurocognitive impairment following head injury: a systematic review.
Neuropharmacological modulation of cognitive deficits after brain damage.
Serum Total Cholinesterase Activity on Admission Is Associated with Disease Severity and Outcome in Patients with Traumatic Brain Injury.
Treatment of attention deficits in neurological disorders.
Brain Ischemia
Ameliorative effects of the centrally active cholinesterase inhibitor, NIK-247, on impairment of working memory in rats.
Correlations Between Cholinesterase Activity and Cognitive Scores in Post-Ischemic Rats and Patients with Vascular Dementia.
Network pharmacology study on the active components of Pterocypsela elata and the mechanism of their effect against cerebral ischemia.
Sub-regional hippocampal vulnerability in various animal models leading to cognitive dysfunction.
Brain Neoplasms
Acetylcholinesterase and butyrylcholinesterase histochemical activities and tumor cell growth in several brain tumors.
Amine oxidase, pressor amines, and cholinesterase in brain tumours.
Expression of muscarinic binding sites in primary human brain tumors.
Breast Neoplasms
Amplification and deletion of the ACHE and BCHE cholinesterase genes in sporadic breast cancer.
Breast cancer metastasis alters acetylcholinesterase activity and the composition of enzyme forms in axillary lymph nodes.
Chemical profile, antiproliferative, antioxidant, and enzyme inhibition activities and docking studies of Cymbopogon schoenanthus (L.) Spreng. and Cymbopogon nervatus (Hochst.) Chiov. from Sudan.
Cholinesterase activity and acetylcholinesterase glycosylation are altered in human breast cancer.
Diagnostic and prognostic significance of serum cholinesterase and lactate dehydrogenase in breast cancer.
Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.
Serum butyrylcholinesterase and zinc in breast cancer.
[Influence of total parenteral nutrition (TPN) on nutritional incidences in patients with recurrent cancer]
Bronchial Hyperreactivity
Ozone inhibition of tissue cholinesterase in guinea pigs.
Bronchial Spasm
Drug-induced bronchospasm.
Bronchitis
A top 5 list for French general practice.
Bronchitis, Chronic
Postlaryngectomy pharyngocutaneous fistula: incidence, predisposing factors, and therapy.
Brucellosis
[Acetylcholine, cholinesterase, catecholamine and vitamin indices in chronic brucellosis]
Budd-Chiari Syndrome
Single-Center Retrospective Study of Clinical and Laboratory Features That Predict Survival of Patients With Budd-Chiari Syndrome After Liver Transplant.
Bulbo-Spinal Atrophy, X-Linked
Acetylcholinesterase inhibitor responsive myasthenia in a Filipino male with X-linked recessive spinal and bulbar muscular atrophy.
Bundle-Branch Block
Changes in cholinesterase activity distribution in ventricular muscle in chronic, experimental bundle branch block in the dog.
CADASIL
Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
Carcinogenesis
Acetylcholinesterase and butyrylcholinesterase histochemical activities and tumor cell growth in several brain tumors.
Amplification and deletion of the ACHE and BCHE cholinesterase genes in sporadic breast cancer.
Breast cancer metastasis alters acetylcholinesterase activity and the composition of enzyme forms in axillary lymph nodes.
Estimation of Serum Butyryl Cholinesterase in Patients with Oral Squamous Cell Carcinoma: A Cross-Sectional Study.
Protein thiols and butryrylcholinestrase in saliva of oral cancer patients.
Role of serum cholinesterase in patients treated with salvage radical prostatectomy.
Significance of serum butyrylcholinesterase levels in oral cancer.
Carcinoma
Acetylcholinesterase and butyrylcholinesterase genes coamplify in primary ovarian carcinomas.
Activated cholinergic signaling provides a target in squamous cell lung carcinoma.
Acute phase proteins and biomarkers of oxidative status in feline spontaneous malignant mammary tumours.
Biological Evaluation of Azomethine-dihydroquinazolinone Conjugates as Cancer and Cholinesterase Inhibitors.
Butyrylcholinesterase: An economical marker of disease activity in oral squamous cell carcinoma before and after therapy.
Cholesteryl esters in human malignant neoplasms.
Cholinesterase activity and acetylcholinesterase glycosylation are altered in human breast cancer.
Diagnostic and prognostic significance of serum cholinesterase and lactate dehydrogenase in breast cancer.
Estimation of Serum Butyryl Cholinesterase in Patients with Oral Squamous Cell Carcinoma: A Cross-Sectional Study.
Expression of cholinesterases in human kidney and its variation in renal cell carcinoma types.
Hypercholinesterasemia in patients with hepatocellular carcinoma: a new paraneoplastic syndrome.
Impact of pretreatment cholinesterase level on survival of inoperable intrahepatic or hepatic-hilar carcinomas treated with three-dimensional conformal radiotherapy.
Modified properties of serum cholinesterases in primary carcinomas.
Oxidative stress and inflammatory response biomarkers in dogs with mammary carcinoma.
Plasma cholinesterase activity in patients with uterine cervical cancer during radiotherapy.
Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.
Preoperative butyrylcholinesterase level as an independent predictor of overall survival in clear cell renal cell carcinoma patients treated with nephrectomy.
Pretreatment serum pseudocholinesterase level as a novel prognostic biomarker for upper tract urothelial carcinoma.
Serum cholinesterase and lactate dehydrogenase levels in cases of squamous cell carcinoma of oral cavity.
Serum cholinesterase levels in patients with cancer.
Significance of preoperative butyrylcholinesterase level as an independent predictor of survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy.
Studies of cholinesterase activity. V. Serum cholinesterase in patients with carcinoma.
Synthesis of New Biscoumarin Derivatives, In Vitro Cholinesterase Inhibition, Molecular Modelling and Antiproliferative Effect in A549 Human Lung Carcinoma Cells.
[A study of the effect of endoxan on the serum cholinesterase activity in gynecologic carcinomas]
[Diagnostic value of biochemical tumor markers in serum of patients with cancer of the ovary]
[Serum cholinesterase activity in stomach carcinoma]
[Serum cholinesterase activity of patients with carcinoma of the cervix]
[Serum cholinesterase in liver cirrhosis and certain carcinomas.]
[The significance of serum cholinesterase in carcinoma patients.]
Carcinoma, Bronchogenic
[Assessment of serum cholinesterase activity in the differential diagnosis of bronchial carcinoma]
[Determination of cholinesterase activity and iron-copper ratio in the differential diagnosis of bronchial carcinoma]
Carcinoma, Hepatocellular
Abnormalities of serum cholinesterase isozyme in liver cirrhosis and hepatoma (Part II).
Arylesterase isoenzymes and activity in normal healthy adults and in patients with cancer and with other diseases.
Cholinesterase activity of liver and blood serum from rats during the development of hepatoma by carcinogen feeding.
Discrimination of liver cirrhosis from chronic hepatitis by measuring the ratio of Aleuria aurantia lectin-reactive serum cholinesterase to immunoreactive protein.
Goodyschle A, a new butenolide with significant BchE inhibitory activity from Goodyera schlechtendaliana.
High cholinesterase predicts tolerance to sorafenib treatment and improved prognosis in patients with transarterial chemoembolization refractory intermediate stage hepatocellular carcinoma.
Histochemical and cytochemical study of butyrylcholinesterase activity in rat hepatocellular carcinomas induced by 3'-methyl-4-dimethylaminoazobenzene.
Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib.
Increase of fucosylated serum cholinesterase in relation to high risk groups for hepatocellular carcinomas.
Increased serum soluble interleukin 2 receptor levels in patients with viral liver diseases.
Quality of life after hepatectomy in patients with hepatocellular carcinoma: implication of change in hepatic protein synthesis.
Some properties and electrophoretic patterns of rat liver esterases in relation to hepatocarcinogenesis by 3'-methyl-4-(dimethylamino) azobenzene.
Survival and prognostic indicators in compensated and decompensated cirrhosis.
The human hepatoma cell line, HepG2, secretes functional cholinesterase.
[Changes in plasma vitronectin, fibronectin, and serum laminin P1 levels and immunohistochemical study of vitronectin in the liver of patients with chronic liver diseases]
[Clinical evaluation of the measurement of hepatosplenic volume ratio by computed tomography]
Carcinoma, Medullary
Acetylcholinesterase and butyrylcholinesterase activities in human thyroid cancer cells.
Carcinoma, Papillary
Acetylcholinesterase and butyrylcholinesterase activities in human thyroid cancer cells.
Carcinoma, Renal Cell
Cholesteryl esters in human malignant neoplasms.
Expression of cholinesterases in human kidney and its variation in renal cell carcinoma types.
Preoperative butyrylcholinesterase level as an independent predictor of overall survival in clear cell renal cell carcinoma patients treated with nephrectomy.
Carcinoma, Squamous Cell
Serum cholinesterase and lactate dehydrogenase levels in cases of squamous cell carcinoma of oral cavity.
Cardiomegaly
Neostigmine and pilocarpine attenuated tumour necrosis factor alpha expression and cardiac hypertrophy in the heart with pressure overload.
Cardiomyopathies
Changes in cholinesterase activities after daunorubicin administration to rabbits.
Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits.
Congenital "histiocytoid" cardiomyopathy: evidence suggesting a developmental disorder of the Purkinje cell system of the heart.
Role of acetylcholine in pyridostigmine-induced myocardial injury: possible involvement of parasympathetic nervous system in the genesis of cardiomyopathy.
Cardiotoxicity
Phosphine toxicity: a story of disrupted mitochondrial metabolism.
Validation of Corrected and Dispersed QT as Predictors of Adverse Outcomes in Acute Cardiotoxicities.
Cardiovascular Diseases
C5 variant is associated with decreased risk of coronary artery disease in outpatients with severe hypercholinesterasemia.
Cholinesterase inhibitors and cardiovascular disease: a survey of old age psychiatrists' practice.
Cholinesterase: Conflicting Aspects of Two Cardiovascular Diseases.
Facile synthesis of new carbon-11 labeled conformationally restricted rivastigmine analogues as potential PET agents for imaging AChE and BChE enzymes.
Serum pseudocholinesterase: high density lipoprotein cholesterol ratio as an index of risk for cardiovascular disease.
Vascular dementia.
[Serum cholinesterase activity in patients with cardiovascular diseases]
[Study of cholinesterase activity in mixed saliva of patients with somatic pathology.]
Catalepsy
Morphine-induced catalepsy in the rat: effect on striatal acetylcholine & cholinesterase.
Striatal cholinergic activity during morphine-induced catalepsy in the rat: development of tolerance.
[Neurochemical aspects of corrective effect of fluoracizine in triphthazine-induced catalepsy in rats]
[The role of catecholamines, acetylcholine and cholinesterase activity in the development of the cataleptic action of triftazin following repeated administration]
Cataplexy
Locus coeruleus neurons: cessation of activity during cataplexy.
Potentiation of a functional autoantibody in narcolepsy by a cholinesterase inhibitor.
Cataract
Cataract due to cholinesterase inhibitors in the guinea-pig.
Effect of a cholinesterase inhibitor on salmonid lens: a possible cause for the increased incidence of cataract in salmon Salmo salar (L.).
Induction of subcapsular cataracts in cynomolgus monkeys by echothiophate.
Risk factors for cataract: a case control study.
[Cholinesterase activity in the humor of the anterior chamber and in the blood in patients with glaucoma and cataract]
Central Nervous System Neoplasms
Pseudocholinesterase activity in cerebrospinal fluid as a biomarker of solid central nervous system tumors in children.
Serum cholinesterase: a potential assistant biomarker for hand, foot, and mouth disease caused by enterovirus 71 infection.
Cerebellar Ataxia
[Familial early onset cerebellar ataxia with hypoalbuminemia]
Cerebral Amyloid Angiopathy
Butyrylcholinesterase K variant and cerebral amyloid angiopathy.
Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy.
Cerebral Infarction
CSF cholinesterase in early-onset and late-onset Alzheimer's disease and multi-infarct dementia of Chinese patients.
[Histochemical demonstration of glial enzyme activity. II. Reagent and neoplastic glia]
Cerebrovascular Disorders
A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes.
A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE.
Cholinergic dysfunction in vascular dementia.
Cholinesterase inhibitors and vascular dementia: another string to their bow?
Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease.
Predictive Factors of Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer's Disease and Mixed Dementia: A One-Year Naturalistic Study.
Predictors of Response to Cholinesterase Inhibitors Treatment of Alzheimer's Disease: Date Mining from the TREDEM Registry.
[Changes in blood cholinesterase activity in cerebrovascular disorders]
Chagas Disease
Cholinesterase inhibition reduces arrhythmias in asymptomatic Chagas disease.
Correlation of plasma butyrylcholinesterase concentration with Acethylcholinesterase H353N polymorphism in the inflammatory response of Chagas disease patients.
[Cholinesterase activity in plasma and erythrocytes of patients with cardiac and undetermined forms of Chagas disease]
Chemical and Drug Induced Liver Injury
[Effect of splenic humoral factors on the cholinesterase activity of liver tissue and blood serum in experimental toxic hepatitis in rats]
[The effect of sodium- and calcium chloride mineral water from the Spalis spring (Druskininkai health resort) on serum pseudocholinesterase activity and the protein-synthesizing function of the liver in experimental acute toxic hepatitis]
Cholangiocarcinoma
Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.
Cholecystitis
[A change in the activity of serum cholinesterase in cholecystitis]
Cholestasis
Clinical studies on plasma protein C. Correlation with serum cholinesterase.
Evaluation of the diagnostic value of serum bile acid in the detection and functional assessment of liver diseases.
Metabolic changes during prolonged total parenteral nutrition in intensive care.
One-year dietary toxicity study with methidathion in beagle dogs.
[Endogenous digitalis-like factor in liver cirrhosis and cholestasis]
[Preprothrombin in acute viral hepatitis B]
Cholesteatoma
Correlation between peri-operative complication in middle ear cholesteatoma surgery using STAMCO, ChOLE, and SAMEO-ATO classifications.
Evaluating hearing outcome, recidivism and complications in cholesteatoma surgery using the ChOLE classification system.
Mapping the ChOLE classification to hearing outcomes and disease-specific health-related quality of life.
Practical applicability of the STAMCO and ChOLE classification in cholesteatoma care.
[Characteristics of diagnosis and surgical treatment of various forms of congenital temporal bone cholesteatoma].
Cholesteatoma, Middle Ear
Correlation between peri-operative complication in middle ear cholesteatoma surgery using STAMCO, ChOLE, and SAMEO-ATO classifications.
cholinesterase deficiency
A case of pseudocholinesterase deficiency in the neonate.
A case of pseudocholinesterase deficiency in the PACU.
A Case of Pseudocholinesterase Deficiency Resulting From Malnutrition.
A conundrum: general or neuraxial anesthesia and the use of ROTEM.
A family with hereditary serum cholinesterase deficiency.
A patient with Churg-Strauss syndrome who underwent endoscopic sinus surgery under general anesthesia -A case report-.
A patient with Sanfilippo syndrome and pseudocholinesterase deficiency, further complicated by post-tonsillectomy haemorrhage.
A third type of serum cholinesterase deficiency in Eskimos.
Acetylcholinesterase activity in cerebrospinal fluid of patients with Alzheimer's disease and senile dementia.
Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide.
Allergic reaction to suxamethonium during emergency caesarean section and pseudocholinesterase deficiency in the same patient.
An unusual presentation of cholinesterase deficiency.
Apnoea due to suxamethonium associated with familial pseudocholinesterase deficiency.
Atracurium for ECT in plasma cholinesterase deficiency.
Awareness during emergence from anaesthesia: significance of neuromuscular monitoring in patients with butyrylcholinesterase deficiency.
Break the Spasm with Succinylcholine, but Risk Intraoperative Awareness with Undiagnosed Pseudocholinesterase Deficiency.
Butyrylcholinesterase deficiency and its clinical importance in anaesthesia: a systematic review.
Butyrylcholinesterase deficiency identified by preoperative patient interview.
Butyrylcholinesterase Deficiency Promotes Adipose Tissue Growth and Hepatic Lipid Accumulation in Male Mice on High-Fat Diet.
Butyrylcholinesterase deficiency.
Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.
Characterization of a novel butyrylcholinesterase point mutation (p.Ala34Val), "silent" with mivacurium.
Cholinesterase deficiency and the Churg-Strauss syndrome.
Cholinesterase deficiency.
Cholinesterase variants: rapid characterisation by PCR/SSCP and evidence for molecular homogeneity.
Comparison between succinylcholine and rocuronium as neuromuscular blocking agents for electroconvulsive therapy in a patient with pseudocholinesterase deficiency.
COMPLETE PSEUDOCHOLINESTERASE DEFICIENCY: GENETIC AND IMMUNOLOGIC CHARACTERIZATION.
Corrected scoliosis, cholinesterase deficiency, and cesarean section: a case report.
Customized anesthetic preservation of ictal threshold in electroconvulsive therapy: role of adjunctive remifentanil with etomidate.
Delayed Emergence From Anesthesia: A Simulation Case for Anesthesia Learners.
Delayed recovery from paralysis associated with plasma cholinesterase deficiency.
Delayed recovery from paralysis by succinylcholine in patient with preoperatively unrecognized and inherited pseudocholinesterase deficiency.
Dental local anesthesia for patients with pseudocholinesterase deficiency.
Discrimination of phenotypes in human serum cholinesterase deficiency.
ECT Modified by Atracurium.
Emergency anaesthesia in a patient with plasma cholinesterase deficiency.
Family of a patient with serum cholinesterase deficiency.
Fresh frozen plasma and edrophonium in a patient with a plasma cholinesterase deficiency.
Genetic analysis of a Japanese patient with butyrylcholinesterase deficiency.
Genetic mutations associated with susceptibility to perioperative complications in a longitudinal biorepository with integrated genomic and electronic health records.
Genetic screening in the Persian Jewish community: A pilot study.
Grand mal seizures after 2-chloroprocaine epidural anesthesia in a patient with plasma cholinesterase deficiency.
Hereditary cholinesterase deficiency.
Hereditary cholinesterase deficiency: a report of a family with two rare genotypes.
Hereditary pseudocholinesterase deficiency discovery after electroconvulsive therapy.
Hereditary serum cholinesterase deficiency associated with severe lipid deposition in the kidney.
Heterozygous pseudocholinesterase deficiency: a case report and review of the literature.
In vitro remifentanil metabolism: the effects of whole blood constituents and plasma butyrylcholinesterase.
LEFT-SIDED AMOEBIC LIVER ABSCESS WITH PULMONARY INVOLVEMENT, PERICARDITIS, AND PSEUDOCHOLINESTERASE DEFICIENCY.
Letter: chloroprocaine and pseudocholinesterase deficiency.
Mivacurium apnoea: a trap for the unwary.
Mivacurium in infants and children.
Mivacurium-induced prolonged neuromuscular block.
Novel mutations in the BCHE gene in patients with no butyrylcholinesterase activity.
Optimizing electroconvulsive therapy in non-suspected pseudocholinesterase deficiency: laryngeal mask use and neuromuscular selection.
Organophosphate exposure with pseudocholinesterase deficiency.
Patient information sheet for plasma cholinesterase deficiency.
Pharmacodynamic and hemodynamic effects of mivacurium in infants anesthetized with halothane and nitrous oxide.
Pharmacogenetics and anaesthetic drugs: Implications for perioperative practice.
Plasma cholinesterase deficiency in a neonate.
Plasma cholinesterase deficiency in a neonate: a follow-up.
Plasma cholinesterase deficiency in a premature neonate.
Plasma cholinesterase deficiency in Turkish patients - a reply.
Plasma cholinesterase deficiency in Turkish patients.
Plasma cholinesterase deficiency.
Plasma cholinesterase deficiency. A possible complication during anesthesia.
Plasma pseudo cholinesterase deficiency leading to seven hour apnoea in a child undergoing adeno-tonsillectomy.
Plasma pseudocholinesterase deficiency associated with diethylstilbestrol therapy.
Postoperative ileus, pregnancy-related cholinesterase deficiency and suxamethonium after-pains. A case report.
Pregnancy-induced cholinesterase deficiency.
Prehospital airway management complicated by reported pseudocholinesterase deficiency.
Premature awakening and underuse of neuromuscular monitoring in a registry of patients with butyrylcholinesterase deficiency.
Prevalence of congenital deficiency in serum cholinesterase.
Problem with detection of an insertion-type mutation in the BCHE gene in a patient with butyrylcholinesterase deficiency.
Prolonged apnea caused by inherited cholinesterase deficiency after strabismus surgery.
Prolonged mivacurium neuromuscular block in children.
Prolonged neuromuscular block associated with cholinesterase deficiency.
Prolonged neuromuscular block associated with mivacurium.
Prolonged neuromuscular block from mivacurium in two patients with cholinesterase deficiency.
Prolonged neuromuscular block in a patient undergoing renal transplantation.
Prolonged neuromuscular block with mivacurium in a patient with cholinesterase deficiency.
Prolonged neuromuscular blockade as a result of malnutrition-induced pseudocholinesterase deficiency.
Prolonged Neuromuscular Paralysis Following Rapid-Sequence Intubation with Succinylcholine (April).
Prolonged paralysis in pseudocholinesterase deficiency.
Prolonged paralysis related to mivacurium: a case study.
Prolonged postoperative apnea with pseudocholinesterase deficiency.
Prolonged postoperative succinylcholine-induced apnea with pseudocholinesterase deficiency.
Properties of the trace enzyme in human serum cholinesterase deficiency.
Pseudocholinesterase activity of human whole blood, bank blood, and blood protein solutions.
Pseudocholinesterase Deficiency - Is Succinylcholine Still Needed to Facilitate Endotracheal Intubation?
Pseudocholinesterase deficiency and electroconvulsive therapy.
Pseudocholinesterase deficiency associated with HELLP syndrome.
Pseudocholinesterase Deficiency Considerations: A Case Study.
PSEUDOCHOLINESTERASE DEFICIENCY IN A OCTOGENARIAN UNDERGOING TOTAL INTRAVENOUS ANESTHESIA; IMPLICATIONS FOR NEUROMONITORING.
Pseudocholinesterase Deficiency in an ECT Patient: A Case Report.
Pseudocholinesterase deficiency in specific populations.
Pseudocholinesterase deficiency.
Pseudocholinesterase deficiency: a comprehensive review of genetic, acquired, and drug influences.
Pseudocholinesterase deficiency: a dangerous, unrecognized complication of the ovarian hyperstimulation syndrome.
Pseudocholinesterase deficiency: an additional preoperative consideration in outpatient diagnostic procedures.
Pseudocholinesterase Deficiency: What the Proceduralist Needs to Know.
Pseudocholinesterases. II. Two cases of pseudocholinesterase deficiency.
Recognizing Pseudocholinesterase Deficiency in the Post-operative Patient: Diagnosis and Management in the ICU.
Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus.
Remifentanil's effect is not prolonged in a patient with pseudocholinesterase deficiency.
Reply: Pseudocholinesterase deficiency in specific populations.
Rocuronium antagonized by sugammadex for series of electroconvulsive therapy (ECT) in a patient with pseudocholinesterase deficiency.
Safe use of landiolol hydrochloride in a patient with marked pseudocholinesterase deficiency.
Screening for plasma cholinesterase deficiency: an automated succinylcholine based assay.
Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Serum cholinesterase deficiency in renal failure.
Serum cholinesterase deficiency. I. Disease and inheritance.
Serum cholinesterase deficiency. II. Pregnancy.
Serum cholinesterase: effect on the action of suxamethonium following administration to a patient with cholinesterase deficiency.
Sick Sinus Syndrome Observed in a Patient with Cholinesterase Deficiency.
Succinylcholine sensitivity and plasma cholinesterase deficiency.
Suxamethonium and mivacurium sensitivity from pregnancy-induced plasma cholinesterase deficiency.
Suxamethonium apnoea in an infant; expression of familial pseudocholinesterase deficiency in three generations.
The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency.
Timing of blood sampling for butyrylcholinesterase phenotyping in patients with prolonged neuromuscular block after mivacurium or suxamethonium.
Transient plasma cholinesterase deficiency in preterm infants.
Unexpected prolonged neuromuscular block after mivacurium: a case report.
Unknown Pseudocholinesterase Deficiency in a Patient Undergoing TIVA with Planned Motor Evoked Potential Monitoring: A Case Report.
Urgent cesarean delivery and prolonged ventilatory support in a parturient with Fontan circulation and undiagnosed pseudocholinesterase deficiency.
Use of atracurium in a patient with plasma cholinesterase deficiency.
Variations in serum cholinesterase activity in different age and sex groups.
Violent fasciculations may not signal pseudocholinesterase deficiency.
[A case of silent gene of heterozygote inherited serum cholinesterase deficiency]
[A case report of a family with serum cholinesterase deficiency]
[A family of adult polycystic kidney disease associated with pseudocholinesterase deficiency]
[A family of pseudocholinesterase deficiency (silent type II)]
[Butyrylcholinesterase deficiency: how to analyse the cholinesterase activity in small children?]
[Cholinesterase deficiency]
[Coexistence of ankylosing pelvispondylitis and cholinesterase deficiency in univitelline twins]
[Delay of decurarization related to pseudocholinesterase deficiency]
[On the problem of pseudocholinesterase deficiency syndrome. Anesthesia accident in a 4-months-old infant during an ophthalmological operation in congenital buphthalmos.]
[Prolonged apnea after suxamethonium administration during staphylococcal toxic shock]
[Prolonged curarisation following succinylcholine injection on butyrylcholinesterase deficiency and potentiated by a lithium treatment: a case report].
[Prolonged neuromuscular block after administration of mivacurium caused by plasma psueudocholinesterase deficiency]
[Prolonged neuromuscular block after mivacurium injection]
[Pseudocholinesterase deficiency; a complication in bronchoscopy in anesthesia and apnea.]
[Pseudocholinesterase deficiency]
[Relation of the functional disorder of external respiration to cholinesterase deficiency in burn patients in the septicotoxemia stage]
[Residual relaxant block due to pseudocholinesterase deficiency - First manifestation in an elderly patient].